View
224
Download
0
Category
Preview:
Citation preview
8/15/2019 Pathological Pain and the Neuroimmune Interface - Nri3621
http://slidepdf.com/reader/full/pathological-pain-and-the-neuroimmune-interface-nri3621 1/15
Pain has been associatewith the immune system since
the time of Celsus, who ientifiepain (dolor) as a cari-
nal sign of acute inflammation. Though acute pain mayoccur in relative isolation from broaer synromes, it
was ientifiein the mi-twentieth century as one of a
constellation of aaptive behaviours, collectively termethe sickness respo nse.
The iea that pain animmunity might be associ-
atebeyonan acute response first arose from clinicalobservations in the 1970s that patients with chronicpain exhibiteother symptoms, in aition to hyper-
algesia , that parallel the classical systemic sicknessresponse — incluing lethargy,epression ananxiety.The concomitance of sickness behaviours with chronic
pain is therefore suggestive of unerlying immuneactivity. Efforts to ientify the origin annature of
the immune meiators involvesoon followe, lea-
ing to the iscovery that elevateperipheral levelsof interleukin-1β (IL-1β) both inucehyperalgesia
perse anmeiatesickness-inucehyperalgesia1,2.Although periphera l sen sitization of pain fibres at local
tissue sites of inflammation has a key role in heighten-ing pain from those regions, these peripheral observa-tions were soon extenewith theiscovery of a central
nervous system (CNS) mechanism of action for IL-1β another cytokines3,4. This research was accompanieby a growing appreciation that the release of cytokinesin the CNS, anthe behavioural effects that occursubsequent to this, might not be solelyepenent on
peripheral signalling (for example, sensory vagal nerve
stimulation an /o r cytokin e release from periph-
eral immune cells), but coulalso be ue to the local
release of cytokines by glia resiing within the CNS5.Glia were first implicatewhen increaseexpression of
astrocyte- anmicroglia-associateactivation markers
was observein the lumbar spinal cors of rats withperipheral nerve injury6,7. The contribut ion of spinal
glia antheir pro-inflammatory proucts to allodynia
anhyperalgesia was then emonstratewhen spi-nal intrathecal injection of inhibitors of gliosis or IL-1receptor antagonist (IL-1Ra) was founto attenuate
the pain behaviours that are associatewith iversepainmoels8–11.
Since these seminal observations, there have been
major avances in unerstaning how glia animmunecells in the CNS responto pain stimuli ancontrib-
ute to pathological pain. In this Review, weetail these
avances in the context of the neuroimmune interface ,which is integral to an appreciation of central immune
signalling. It shoulbe notethat neuroimmune inter-actions are crucial to inflammation-inuceperiph-
eral sensitization anpathophysiological changes at thesite of peripheral nerve injury. However, this Reviewis restricteto the composition of the neuroimmune
interface in the CNS, anhow its constituent cellsbecome reactive ancontribute to chronic pain. The
protective role of immune signalling in neuropathicpain, together with methos to pharm acologicallytarget the neuroimmune interface for superior pain
control are also iscusse.
Celsus
Aulus Cornelius Celsus was
afirst century Roman
encyclopaedist who gathered
extensive writings from the
Greek emp ire and t ranslated
them into Latin. In his great
work De Medicina, he
characterized the four cardinal
signs of inflammation: heat,
pain, swelling and redness.
Pathological pain and theneuroimmune interfacePeter M.Grace 1 ,2 , Ma rk R.Hutchinson1 ,2 , Ste ven F.Maier1 a nd Linda R.Watkins 1
Abstract | Reciprocal signalling between immunocompetent cells in the central nervous
system (CNS) has emerged as a key phenomenon underpinning pathological and chronic
pain mechanisms. Neuronal excitability can be powerfully enhanced both by classical
neurotransmitters derived from neurons, and by immune mediators released from
CNS-resident microglia and astrocytes, and from infilt rating cells such as Tcells. In thisReview, we discuss the current understanding of the contribution of central immune
mechanisms to pathological pain, and how the heterogeneous immune functions of different
cells in the CNS could be harnessed to develop new therapeutics for pain control. Given the
prevalence of chronic pain and the incomplete efficacy of current drugs — which focus on
suppressing aberrant neuronal activity — new strategies to manipulate neuroimmune pain
transmission hold considerable promise.
1Department of Psychology
and Neuroscience, and
TheCenter for Neuroscience,
University of Colorad o
Boulder, Boulder
803 09–0 345 , USA.2School of Medical Sciences,
University of Adelaide,
Adelaide 50 05 , Australia.
Correspondence to P.M.G.
e-mail:
peter.grace@colorado.edu
doi:10.1038/nri3621
Published online
28 February 2014
REVIEWS
NATURE REVIEWS | IMMUNOLOGY VOLUME 14 | APRIL 2014 | 217
8/15/2019 Pathological Pain and the Neuroimmune Interface - Nri3621
http://slidepdf.com/reader/full/pathological-pain-and-the-neuroimmune-interface-nri3621 2/15
Sickness resp onse
A defence mechanism
triggered by the recognition
of anything foreign to the host.
An organized constellation
of responses initiate d by
the immune system but
co-ordinate d a nd p artially
created by the brain,
includingphysiological
responses (for example,
fever,increased s leep,
hyperalgesia and allodynia),behavioural responses (for
example, decreased social
interaction, sexual activity,
an dfood and water intake),
and hormonal responses
(increased release of classic
hypothalamo–pituitary–
adrenal and sympathetic
hormones).
Hyperalgesia
Increased pain from a
stimulusthat normally
provokes p ain. A form o f
nociceptive hypersensitivity.
Physiological pain processingPain (either nociceptive pain or inflammatory pain) is pro-tective anaaptive, warning the iniviual to escape
the pain-inucing stimulus anto protect the injure
tissue site uring healing. The basic scientific uner-staning of sensory processing anmoulation hasbeen ramatically improveby the evelopment of
pain assays that recreate some elements of clinical painsynromes (BOX1 ).
Painful stimuli (for example, mechanical, thermal
anchemical) are initially transuceinto neuronalelectrical activity anconuctefrom the peripheral
stimulus site to the CNS along a series of well-character-
izeperipheral nociceptive sensory neurons (first-orderprimary afferent neurons). The nociceptive signal is then
transmitteat central synapses through the release of avariety of neurotransmitters that have the potential to
excite second-order nociceptive projection neurons in thespinal dorsal horn or hindbrain (FIG.1). This process ofnoci-
ception can occur through several mechanisms involving
glutamate anneuropepties (for example, substance Por calcitonin gene-relatepeptie (CGRP)). Glutamate
activates postsynaptic glutamate AMPA (α-amino-3-hyroxy-5-methyl-4-isoxazole proprionic aci) ankainate receptors on secon-orer nociceptive projec-
tion neurons. Interestingly, these receptor systems are
not all engageequally in response to ifferent types of
pain. Moification of the nociceptive signal can occur
at the level of the spinal corthrough activation of localGABAergic (that prouce γ-aminobutyric aci) angly-
cinergic inhibitory interneurons.
Secon-orer nociceptive projection neurons projectto supra-spinal sites, which further project to cortical
ansubcortical regions via third-order neurons, enabling
the encoing anperception of the multiimensionalpain experience. Secon-orer nociceptive projectionneurons can be further moulatethrough the acti-
vation of escening serotonergic annorarenergicprojections to the spinal cor, which can influence theresponse to anperception of pain (FIG.1). For recent
reviews that escribe these processes in etail, seeREFS12,13 .
Pathological pain processingPain can extenbeyonits protective usefulness, last-
ing for a perioof weeks to years — well beyontheresolution of the initial injury. In this case, pain is mala-
aptive anis believeto result from abnormal func-tioning of the nervous system. In the UniteStates alone,such persistent pain is estimateto affect ~37% of the
population; representing an economic buren of up toUS$635billion per year14. Perhaps the most well-stuieexample is neuropathic pain, which is relatively commonanarises as a irect consequence of a lesion or iseaseaffecting the somatosensorysystem.
Intense, repeateansustaineactivity of first-orer neurons elicits well-characterizechanges inneuronal anbiochemical processing at centr al syn-
apses anescening projections, transitioning these
sites into a pain-facilitatory state12,13. In the spinalorsal horn , these changes are collectively known as
centra l sensitization anwindup . These processes involve
the phosphorylation of a range of receptors, incluingNMDA (N-methyl-d-aspartate), AMPA an /or kainate
receptors, which increases synaptic efficacy by altering
channel opening time, increasing burst firing, remov-ing the Mg2+-meiatechannel blockae at the NMDAreceptor, anpromoting trafficking of receptors to
the synaptic membrane15. Uner such circumstances,low-thresholsensory (Aβ) fibres that are activatebyinnocuous stimuli are able to activate high-threshol
nociceptive neurons, owing to either a strengtheneexcitatory input or the lowereexcitation thresholof
nociceptive projection neurons15. Central sensitization
is maintaineby ongoing stimuli, such as spontaneousactivity arising from sensory fibres or locally releaseimmune meiators (see below), which are responsi-ble for the persistence anspreaof neuropathic pain
beyonthe initial injurysite.Although the importance of these neuronal pain
facilitation mechanisms is unispute, not all symptoms
anmechanisms can be explainesolely by such neu-ronal mechanisms. These neuronal pathophysiological
mechanisms are being supplementeby an apprecia-tion for the role of central immune signalling, such thatneuropathic pain is now consiereas a neuroimmune
isorer16.
Box 1 | Precl ini cal pain assays and measures
The development of preclinical pain assays — the experimental procedures by which
pain is induced in the subject — has typically occurred over several distinct phases154.
Init ial studies of pain used acute assays, involving t he application of a noxious stimulus
(which may be thermal, mechanical, electr ical or chemical) to an accessible body part
(usually the hindpaws, tail or abdomen); or inflammatory assays that directly activate
nociceptors (for example, treatment with formalin or capsaicin) or the immune system
(for example, treatment with complete Freund’s adjuvant or carrageenan). In orderto study the unique pathophysiological mechanisms of neuropathic pain that arise
owing to dif fering adaptations resulting from injury to nervous — compared wit h
other somatic — tissues, as well as increased pain duration, three main assays were
developed: first, chronic constriction injury, in which loose ligatures are tied around the
sciatic nerve to produce damage to some of the axons by inducing swelling and then
strangulation155; second, partial sciatic nerve ligation, in which a tight ligature is applied
through approximately one-half of t he proximal sciatic nerve156; and finally, spinal nerve
ligation, involving tight ligation of the lumbar spinal nerves (L4 and L5), close to the
dorsal root ganglion157. These assays have undergone continual development, and have
been adapted to study orofacial pain and heterogeneous pain thresholds154,158. The
recognition that existing assays can model ext remely rare pain syndromes, but lack face
validit y for t he more common pain syndromes, has led to more direct attempts to mimic
the pain associated with specific disease states, often by attempting t o induce the
disease, injury or the physiological state it self (for example, chemotherapy-induced
neuropathic pain or multiple sclerosis159,160)154.Furthermore, modern studies of chronic pain use acute assays to quantify
hypersensit ivit y, which is the most common preclinical end point. The pain measures
typically used are evoked spinal reflexes (for example, the von Frey test for mechanical
allodynia and the Hargreaves test for thermal hyperalgesia), spino-bulbospinal reflexes
(for example, jumping or abdominal stretching), or simple innate behaviours (for
example, licking, guarding or vocalization). As part of the general crit ique of pain
models, the validit y of current pain measures is presently being re-examined, and
alternative measures are being developed to reflect supraspinal pain processing,
such as operant measures (for example, conditioned place aversion161), spontaneously-
emitted behaviours (for example, facial grimacing or suppressed voluntary wheel
running162,163), as well as complex states affected by chronic pain (for example,
altered social interactions or sleep disruptions164)154,165.
REVIEWS
218 | APRIL 2014 | VOLUME 14 www.nature.com/reviews/immunol
8/15/2019 Pathological Pain and the Neuroimmune Interface - Nri3621
http://slidepdf.com/reader/full/pathological-pain-and-the-neuroimmune-interface-nri3621 3/15
8/15/2019 Pathological Pain and the Neuroimmune Interface - Nri3621
http://slidepdf.com/reader/full/pathological-pain-and-the-neuroimmune-interface-nri3621 4/15
oglial cell
T cell
CNSparenchyma
Systemiccirculation
P2X4R7
P2Y13RP2Y12R
TLR2 oTLR4
Fn
IL-1R1
CCC
CCR7
CX3CR1
MMP2,MMP9
IL-1β orIL-18
TNF,BDNF
TLR4
CCR2 orCX3CR1
TN
CCR2
CX3CR1
CCR2
LFA1
ICAM1
REVIEWS
220 | APRIL 2014 | VOLUME 14 www.nature.com/reviews/immunol
8/15/2019 Pathological Pain and the Neuroimmune Interface - Nri3621
http://slidepdf.com/reader/full/pathological-pain-and-the-neuroimmune-interface-nri3621 5/15
Gliosis
The transition from a role
inphysiological maintenance or
surveillance to a reactive
phenotype that is characterized
by changes incell number,
morphology, phenotype,
motility, protein expression
and by the release o f
immunoregulatory prod ucts.
Neuroimmune interface
Proposed to de scribe the
bidirectional, modulatory
signalling between immune
cells and neurons. We a rgue
that su ch interfaces are formed
in the central nervous system
and can exp lain the sensoryada ptations unde rlying
pathological pain.
Central immune signalling
The process and
consequencesof immune
mediator release byreactive
immunocompetent cells in
the cen tral nervous system.
Nociceptive pain
Physiological pain produced
byintense noxious stimuli
thatactivate high-threshold
nociceptor neurons.
anregional heterogeneity throughout the parenchyma,presumably to coorinate iverse responses to insult18.
Uner a basal surveillance state, the cytoarchitecture
of microglia allows them to continuously sample theextracellular space for perturbations19. Transition to a
state of reactive gliosis involves changes in cell number,
morphology, phenotype anmotility, the expressionof membrane-bounanintracellular signalling pro-
teins (for example, mitogen-activateprotein kinases
(MAPKs)), anthe release of immunoregulatory pro-ucts, such as cytokines anchemokines. A commonmarker of astrogliosis is increaseexpression of glial
fibrillary aciic protein (GFAP), which is inicative ofalteremorphology. Microgliosis is often correlatewithincreaseexpression of CD11b anallograft inflamma-
tory factor1 (AIF1; also known as IBA1)20,21. It shoulbe notethat the functional relationship between the
expression of such markers annociceptive hypersensi-
tivity is currently unclear, anin certain circumstancesthere seems to be no connection between thetwo22.
Enothelial cells responto chemokines such asCC-chemokine ligan2 (CCL2; also known as MCP1)
anCX3C-chemokine ligan1 (CX
3CL1; also known
as fractalkine) by increasing expression of receptorsantethering proteins that facilitate transenothelial
migration of monocytes anTcells across the bloo–CNS barrier. CCL2 anCX
3CL1 also attract monocytes
anTcells to the CNS, where they interact with localimmunocompetent cells to facilitate the propagationanifferentiation of the immune response, which
eventually leas to moification of neuronal activity23,24.
The presence of specific Tcell subpopulations at the
neuroimmune interface is not well establisheanhas
primarily been efineon the basis of cytokine expres-sion. For example, the respective T helper 1 (T
H1), T
H2
anTH17-associatecytokines interferon-γ (IFNγ), IL-4
anIL-17 have been etectein roent lumbar spinalcors after peripheral nerve injury or inflammation25–28.
A specific role for regulatory T (TReg
) cells at the neuro-
immune interface has not yet been establishe, butsystemic expansion of T
Reg cells was founto attenuate
nerve injury-inucenociceptive hypersensitivity29.
Although not systematically characterize, the natureof the precipitating injury or insult is likely to influencethe cell populations that are recruiteto the spinal or-
sal horn. For example, pain is associatewith both spi-nal corinjury anperipheral ner ve injury. However,
infiltration of neutrophils into the spinal coris onlyassociatewith spinal corinjury, which coulbe ueto ifferential expression of cell ahesion molecules30,31.
Interestingly, nociceptive threshols have been suc-cessfully preicteon the basis of peripheral immune
cell activity in preclinical stuies, anin both healthyvolunteers anpatients with chronic pain 32–35. Finally,neurons not only responto neurotransmitterserive
from other neurons, but also express a wie range ofconstitutive aninucible classical immune signalling
receptors anligans, anare capable of moulatinglocal immune activity via both contact-epenent ancontact-inepenent mechanisms36,37.
Transition of immunocompetent cells in the spinalorsal horn to a reactive phenotype has been implicatein neuropathic pain8–11,23,38–42. Consierable investiga-
tion has aressekey questions of how such central
immune signalling is initiateafter a peripheral nerveinjury, anthe mechanisms by which it contributes to
central sensitization.
The neuroimmune interf ace in pathological painFollowing peripheral nerve injury, high-threshol
activity or amage of first-orer neurons initiates cen-tral immune signalling at the level of innervation43–45.Although astrocytes anTcells may respon to
neuronal signals, microglia have been ientifieas thefirst responers to a host of neuronally-erivemeia-tors, incluing matr ix metalloproteinase 9 (MMP9),
neuregulin 1, chemokines, ATP anenogenous angersignals (amage-associatemolecular patterns (DAMPs;
also known as alarmins))46,47. Upon etection of such
signals, microglia transition into a state of reactive gliosis.Peripheral immune cell infiltration anastrogliosis soon
follow, owing to the release of cytokines, chemokines,DAMPs aninflammatory meiators from reactive
microglia23,42 (FIG.2).
Chemokines, ATP and initiation of central immune sig-
nalling. Following the transuction of noxious stimuli,ATP anchemokines — such as CCL2, CX
3CL1 an
CCL21 (also known as SLC an6Ckine) — are releasefrom central terminals in the spinal orsal horn, aninuce signalling via G protein-couple receptors
(GPCRs) anligan-gateion channels. The expression
Figure 2 | Init iat ion of central immune signall ing. Damage to or high-thresholdactivation of first-order neurons by noxious stimuli induces the release of ATP,CC-chemokine ligand 2 (CCL2), CCL21 and neuregulin 1 (NRG1), as well as endogenousdanger signals to initiate central immune signalling in the dorsal horn of the spinal cord.CCL2 is released and rapidly upregulated by neurons following depolarization, andsignals via its cognate receptor CC-chemokine receptor 2 (CCR2) on microglia.CX
3C-chemokine ligand 1 (CX
3CL1) is liberated from the neuronal membrane by matrix
metalloproteinase 9 (MMP9) and MMP2 and by microglial cell-derived cathepsin S (CatS)
and signals via CX3C-chemokine receptor 1 (CX3CR1), which is expressed by microglia.CCR2 and CX3CR1 signalling also induces the expression of integrins (such as
intercellular adhesion molecule 1 (ICAM1) and platelet endothelial cell adhesionmolecule (PECAM1)) by endothelial cells, allowing the transendothelial migration ofTcells. Neuronal cell release of CCL21 stimulates local microglia via CCR7, andinfilt rating Tcells are activated via CXCR3. ATP induces microgliosis via the purinergicreceptors P2X
4R, P2X
7R, P2Y
12R and P2Y
13R. Microglia express Toll-like receptor 2 (TLR2)
and TLR4 leading to activation of the MYD88 pathway after detection of endogenousdanger signals, such as heat shock protein 60 (HSP60), HSP90, high mobility group box 1(HMGB1) and fibronectin. Following the detection of such signals, many int racellularpathways are recruited including SRC family kinases (SRC, LYN and FYN), MAPKs(extracellular signal-regulated kinase (ERK), p38 and JUN N-terminal kinase (JNK))and the inflammasome. This leads to phenotypic changes, increased cell motility andproli feration, altered receptor expression, the activation of transcript ion factors,such as nuclear factor-κ B (NF-κ B), and the production of inflammatory mediators
(such as interleukin-1β, (IL-1β), IL-18, tumour necrosis factor (TNF) and brain-derivedneurotrophic factor (BDNF)). Interleukin-1 receptor (IL-1R1) signalling reduces microglialcell expression of G protein-coupled receptor kinase 2 (GRK2), which is a negativeregulator of G protein-coupled receptors (GPCRs), including chemokine receptors.This leads to sustained GPCR signalling, and the exaggerated and prolonged productionof pro-inflammatory mediators. The release of soluble mediators also provides afeedback mechanism by which further immune cells are activated.
◀
REVIEWS
NATURE REVIEWS | IMMUNOLOGY VOLUME 14 | APRIL 2014 | 221
8/15/2019 Pathological Pain and the Neuroimmune Interface - Nri3621
http://slidepdf.com/reader/full/pathological-pain-and-the-neuroimmune-interface-nri3621 6/15
Inflammatory pain
Occurs in response to tissue
injury and the subsequent
inflammatory response.
First-order primary
afferent neurons
Sensory neurons the cell
bodies of which lie in the
trigeminal or spinal dorsal
root ganglia, with projections
that transmit nociceptive
signals from the periphery
(the p eripheral terminal) to
the spinal cord (the central
terminal).
Central synapse s
The synapses between
first-order neurons, whichformthe p resynaptic terminal,
and nociceptive projection
neurons, which form the
postsynap tic terminal.
Second-order nociceptive
projection neuron s
Neurons p rojecting from the
medullary dorsal horn or
the superficial laminae of the
spinal dorsal horn to the
brainstem or th alamic nuclei.
Spinal dorsal horn
Two longitu dina l sub divisions
of grey matter in the p osterior
part of the spinal cord that
receive terminals from afferent
fibres originating from each
side of the body that encode
several types of sensory
informa tion, including
nociception.
Hindbrain
Also known as the
rhombencephalon. An area
rostral to the spinal cord that
gives rise to the cerebellum,
pons and medulla.
Nociception
The neural process o fencodingnoxious mechanical,
thermal and /or chemical
stimuli that occurs in afferent
fibres, which send signals to
the cen tral nervous system.
Pain is expressed as the
complex emotional and
beha vioural response to the
central integration of
nociceptive signals.
Third-order ne urons
Sensory ne uronal projections
originat ing from th alamic
nuclei.
of CCL2 anCX3CL1 is not only inucible, but these
chemokines can also be constitutively expresseby first-
orer neurons48–52. Genetic or pharmacological manipu-lation of the receptors for CCL2 anCX
3CL1 attenuates
microgliosis anthe ensuing evelopment of nocicep-
tive hypersensitivity after peripheral nerve injury24,48–53.CX
3CL1 may be a seconary signal to microgliosis, as
cleavage of this chemokine from neuronal membranes
typically requires the release of cathepsin S (a lysosomalprotease), which is prouceby P2X
7 receptor (P2X
7R)-
stimulatemicroglia51,54. MMP9 anMMP2 prouce
by neurons anastrocytes may also promote CX3CL1
liberation55. Interestingly, the pro-inflammatory role ofCX
3CL1 has largely beenefinewithin the pain fiel, as
this neuronally tetherechemokine is commonly vieweas a homeostatic regulator that maintains a ‘surveillance’
phenotype in microglial cells. However, it has been pos-itethat CX
3CL1 can haveifferent functions in its teth-
ereancleavestates56. CCL21 has also been implicatein nociceptive hypersensitivity. It is releasefrom thecentral terminals of injureneurons, anstimulates an
attracts local microglia aninfiltrating Tcells57,58.Resient microglia also express a range of ionotropic
anmetabotropic purinergic receptors — P2X anP2Y
purinoceptors, respectively — that shape microgliosis59.Hence, neuronal release of ATP, either as a neurotransmit-
ter or as a consequence of cellamage, is a crucial molecu-lar substrate for early microgliosis60,61. P2X
4R anP2X
7R
have been implicatein neuropathic pain by experiments
that blockereceptor function pharmacologically anbygenetic ablation22,40,62–64. However, certain evelopmentalfactors shoulbe consierewhen interpreting knock-
out ata anhypo-functional variants. For example,
nitric oxie prouction by enothelial cells is impaireinP2X
4
R-eficient mice65. This makes itifficult to interpret
the irect effects of P2X4R activation on microglia using
these animals, asisruption of enothelial cell functionwill perturb the cellular milieu in the CNS after periph-
eral nerve injury. Furthermore, some P2X7R-eficient
mouse strains express a splice variant, which allows themto retain P2X
7R function66. Intrathecal aoptive transfer of
ATP-stimulatemicroglia into naive rats, which inuce
robust alloynia, showethat these effects are local-izeto microglia39,40. Furthermore, activation of P2X
7R,
expresseby microglia, inucethe release of IL-1β an
cathepsin S, which are key contributors to nociceptivehypersensitivity54,67. The evelopment of alloynia also
correlates temporally with an increase in spinal micro-
glial cell expression of P2X4R22,40. P2Y12receptor (P2Y12R)
anP2Y13
R expression by microglia rapily increases after
peripheral nerve injury, anpharmacological or geneticisruption of signalling through these receptors prevents
the evelopment of alloynia68,69. These ata proviecompelling evience that P2 receptor activation is crucialto microgliosis anthe aetiology of neuropathicpain.
Toll-like receptors and the initiation of central immune
signalling. Damage first-orer sensory neuronsmay also release extracellular matrix molecules anDAMPs, which are etecteby Toll-like receptors
(TLRs) expresseby immunocompetent cells within the
CNS70,71. TLRs responto iverse invaing pathogens
anDAMPs, anrely on receptor imerization, such as
that of the co-receptor CD14 with myeloiifferentia-tion protein 2 (MD2; also known as LY96), to achieve
specificity in agonist recognition71. Spinal DAMPs
implicatein roent pain moels inclue high mobilitygroup box 1 (HMGB1), fibronectin anthe heat shock
proteins HSP60 anHSP90. Neuronal HMGB1 expres-
sion is increasein the spinal corafter peripheral nerveinjury, antemporally correlates with the evelopmentof alloynia in bone cancer aniabetic neuropathy
assays72–74. Such pain is attenuateby intrathecal aminis-tration of an HMGB1-specific neutralizing antiboy73,74.Fibronectin has been shown to upregulate spinal micro-
glial cell expression of P2X4R59. After peripheral nerve
injury, HSP60 is upregulatein the spinal coranintrathecal HSP90 inhibition reverses alloynia75,76.
To ate, only TLR2 anTLR4 have been implicatein gliosis after peripheral nerve injury. IncreaseTLR4
expression correlates temporally with the evelopmentof nociceptive hypersensitivity after peripheral nerve
injury77. In aition, spinal expression of CD11b anGFAP is ecreasein nerve-injuremice with geneticisruption of Tlr4 or Cd14, which is inicative of attenu-
ategliosis in these animals72,77,78. This is not simply a con-sequence ofisrupteTLR4 signalling at the site of nerve
injury, as nerve injury-inucealloynia can be preventeor reverseby intrathecal aministration of TLR4 antago-nists79,80. Furthermore, gliosis annociceptive hypersensi-
tivity is attenuatein nerve-injureTLR2-eficient mice,anpro-inflammatory cytokine expression is abolisheinTLR2-eficient microglia treatewith conitionemeia
from amagesensory neurons43. Activation of alterna-
tive immune signalling pathways in the absence of TLRsshoulalso be consiere. For example, comparewith
wil-type controls, TLR4-eficient mice have elevate
levels of TH1- anT
H2-type cytokines uring infection81.
Furthermore, TLR4-eficient mice stillevelop alloynia,
although unlike in wil-type mice it can no longer be
inhibiteby IL-1Ra82. These reports inicate that cau-tion must be exercisewhen interpreting the influenceof TLRs on nociception when the conclusions are solely
rawn from knockoutata.Provocative ata also suggest that neurons may be
capable of irectly sensing DAMPs, owing to the expres-
sion of a wie range of TLRs anTLR aaptor proteinsby primary sensory afferents, such as trigeminal sensory
neurons andorsal root ganglia (DRG) neurons in both
humans anroents (for a review, see REF.71 ). At present,expression of TLRs in spinal orsal horn secon-orer
projection neurons remains to be shown. Neuronal TLRexpression has not only beenemonstrateat the mRNA
level anthrough the use of antiboies (which currentlylack suitable specificity, making antiboy-baseetec-tion suspect), but also by bining assays anmeasures
of function, such as patch clamp electrophysiology71,83,84.In DRG neurons, TLR3 expression increaseafter injury,
anactivation of TLR4, TLR7 anTLR9 in DRG neuronseliciteintracellular calcium accumulation, inwarcur-rents, sensitization of transient receptor potential cation
channel subfamily V member 1 (TRPV1), anprouction
REVIEWS
222 | APRIL 2014 | VOLUME 14 www.nature.com/reviews/immunol
8/15/2019 Pathological Pain and the Neuroimmune Interface - Nri3621
http://slidepdf.com/reader/full/pathological-pain-and-the-neuroimmune-interface-nri3621 7/15
Central sensitization
A period o f facilitate d
transmission in nociceptive
projection neurons th at is
characterized by a decreased
activation threshold and an
increase d responsiveness to
nocicep tive stimuli.
Windup
Cumulative increases in
memb rane dep olarization
elicited by repeated C-fibre
stimulation.
Masseter
A facial muscle that has a
ma jor role in chewing.
of IL-1β, CCL5, CXCL10 anPGE2 (REFS71 , 83 , 84 ).
Although neuronal TLR7 has been shown to signal
through MYD88, the intracellular signalling events thatare ownstream of other neuronal TLRs, as well as their
consequences for action potential generation, have not yet
been fully characterize85. However, it is clear that the TLRsignalling pathways requireby innate immune cells are
not necessarily ientical to those of neuronal TLRs. For
example, in mice, DRG neurons require myeloiiffer-entiation factor 1 (MD1; also known as LY86) anCD14for functional TLR4 signalling, whereas TLR4 signalling
by innate immune cells requires MD2 anCD14 (REF.86).
Intra cellular signalling pathways underlying gliosis.
Given the iverse array of neuronal animmune cell-
erivesignals escribeabove, it is no surprise that
a wie range of intracellular signalling pathways canbe activate, leaing to gliosis anthe prouction ofimmune meiators41. MAPK signalling pathways (such
as those involving extracellular signal-regulatekinase(ERK), p38 anJUN N-terminal kinases (JNK)) in
glia have an important role in intracellular signalling,
leaing to the activation of transcription factors, such
as nuclear factor-κ B (NF-κ B), that promote the expres-
sion of a wie array of genes encoing pro-inflammatoryproucts (such as cytokines anbrain-derived neurotrophic
factor (BDNF)). In various moels of peripheral pain,
spinal microglia show increasephosphorylation of SRCfamily kinases (namely, SRC, LYN anFYN), which are
upstream of ERK28,87,88. Furthermore, specific inhibition of
SRC family kinases in microglia attenuates nerve injury-inucealloynia by preventing long-term potentiationin spinal orsal C-fibres88,89. Aaptations in intracellular
signalling may also contribute to the tr ansition fromacute to chronic pain (BOX2 ).
Pain enhancement at the neuroimmune interfaceGlia animmune cells exert their influence on neural
pain processing circuitry via soluble meiators that arereleasefor months after injury as a consequence ofgliosis90. A recent stuy has also raisethe intr iguing
possibility that neurons may be autonomous ‘immunesensors’, acting inepenently of glial animmune cell
influences. Pain inuceby Staphylococcus aureus wasshown not to be initiateby an immune cell intermei-ary, but rather by irect activation of first-orer noci-
ceptive neurons by bacterially eriveN-formylatepepties signalling at formyl peptie receptors, as well as
byα-haemolysin91. Nonetheless, meiatorserivefromglia animmune cells iffuse anbinto receptors onpresynaptic anpostsynaptic terminals in the spinal or-
sal horn to moulate excitatory aninhibitory synaptictransmission. This results in nociceptive hypersensitiv-ity that is characteristic of central sensitization (FIG.3).
Notably, comparewith classical neurotransmitters,
immune meiators can moulate spinal corsynaptictransmission at substantially lower concentrations41.
Enhanced excitatory synaptic transmission. Immunemeiators, such as tumour necrosis factor (TNF),
IL-1β, IFNγ, CCL2 anreactive oxygen species (ROS)
can irectly moulate excitatory synaptic transmissionat central terminals, principally by enhancing gluta-mate release92–96. Such effects are meiateby a func-
tional coupling between IL-1 receptors anpresynapticNMDA receptors, anpresynaptic TRPV1 antransientreceptor potential cation channel subfamily A member 1
(TRPA1) activation that leas to Ca2+-epenent gluta-mate release95–98. Immune meiators such as TNF, IL-1β,
IL-17, prostaglanin E2 (PGE2), CCL2 anCXCL1 also
irectly sensitize postsynaptic terminals of central syn-apses by several key mechanisms. These inclue the
increasetrafficking ansurface expression of AMPAreceptors (incluing those permeable to Ca2+), which
reners neurons vulnerable to excitotoxicity, as well asthe phosphorylation of the NR1 anNR2A or NR2Bsubunits of the NMDA receptor27,99–105. Excitatory syn-
aptic transmission is also inirectly enhancefollowingastrogliosis, as the spinal astrocyte glutamate transport-
ers excitatory amino acitransporter 1 (EAAT1) anEAAT2 are persistently ownregulateafter peripheralnerve injury, leaing to excitotoxicity annociceptive
hypersensitivity106,107.
Box 2 | Acute to chronic pain t ransit ion and t he neuroimmune interf ace
The neurobiological mechanisms underlying the transit ion f rom adaptive acute pain
to maladaptive chronic pain are not yet well understood, as most people recover
from a lesion or disease affect ing the somatosensory system without going on t o
develop chronic neuropathic pain. For example, only ~9% of pat ients (uncorrected
for age) with acute herpes zoster virus infect ion continue to experience pain 1year
after the initial infection166. This raises an intriguing question: what makes these
patient subsets different?
One hypothesis is that unregulated gliosis may sustain central sensit ization. For
instance, G protein-coupled receptor kinase 2 (GRK2; also known asβ-adrenergic
receptor kinase 1) is an enzymatic regulator of t he homologous desensit ization of many
G protein-coupled receptors (GPCRs) that are involved in pain signalling (for example,receptors for chemokines and prostaglandins and some glutamate receptors). Such
desensitization of GPCRs by GRK2 protects cells against overstimulation. Peripheral
inflammation or nerve injury induces a 35–40% reduction in GRK2 expression in lumbar
dorsal horn microglia, as a secondary adaptation of interleukin-1 receptor 1
(IL-1R1)-mediated signalling in these cells167–169. This decrease in GRK2 expression
prolongs nociceptive signalling, as shown by several studies in which peripherally
induced hyperalgesia was prolonged in mice with a specific deletion of GRK2 in
microglia, macrophages and granulocytes169. Downregulation of GRK2 may lead to
uncontrolled stimulation of microglia and, therefore, to the exaggerated and prolonged
production of pro-inflammatory mediators.
Another answer may lie in the immunological history of patients with chronic
neuropathic pain. There is emerging evidence that after a primary immune challenge,
microglia may retain enhanced transcript ional activit y or epigenetic modifications that
confer a heightened response to subsequent immune challenges20. Such immune
priming (also called immune training or postactivation) by stress, ageing, il lness or injuryfollowed by a somatosensory lesion or disease (or vice versa) may lead to chronic pain in
clinical populations, and has been modelled in several preclinical studies. Prior
treatment with corticosterone potentiated lipopolysaccharide (LPS)-induced allodynia
and increased spinal cord levels of interleukin-1β (IL-1β) and IL-6 (REFS170,171). Such
potentiated allodynia was inhibited by co-administration of the IL-1 receptor antagonist
protein (IL-1Ra)170. In a similar manner, prior exploratory abdominal surgery (laparotomy)
also potentiated LPS-induced allodynia, which was attenuated by minocycline (a
broad-spectrum tetracycline antibiotic and anti-inflammatory agent) administered
either at the time of surgery or LPS administration172. Prior t reatment with morphine
(which induces microgliosis; BOX3 ) has also been shown to potentiate allodynia induced
by hindpaw or masseter inflammation, as well as peripheral nerve injury173. Although it is
likely that such primed microglia retain enhanced transcript ional activity, these changes
may only be subtle and the intracellular mechanisms involved are not well understood.
REVIEWS
NATURE REVIEWS | IMMUNOLOGY VOLUME 14 | APRIL 2014 | 223
8/15/2019 Pathological Pain and the Neuroimmune Interface - Nri3621
http://slidepdf.com/reader/full/pathological-pain-and-the-neuroimmune-interface-nri3621 8/15
Blood– CNS ba rrier
A barrier formed by ast rocyte
end-feet and the tight junctions
between endothelial cells lining
blood vessels that excludes
constituents of the syste mic
circulation from entry into the
central nervous system (CNS).
It forms an important
boundary between the
sensitive microenvironment
of the CNS and the relatively
volatile environment of the
systemic circulation.
Trigemina l sens ory neuron s
Neurons found in the
trigeminal nerve tha t med iate
facial sensation and motor
functions, including biting and
chewing.
Dorsal root ganglia
(DRG).The cell bodies of
sensory neurons are collected
together in pa ired ganglia tha tlie alongside the spinal cord.
Each cell body is enca psulated
by satellite glia, with the entire
ganglia being surrounded by a
capsule of connective tissue
and a perineurium.
Brain-derived
neurotrophicfactor
(BDNF). A neurotrophin
expressed at high levels in the
central nervous system tha t
is vital for the growth and
survival of neurons, and has
been implicated in many
forms of synaptic plasticity.
C-fibres
Small diameter, unmyelinated
primary afferent sensory fibres,
with small cell bod ies in the
dorsal root ganglion. Some
C-fibres are m echa nically
insensitive, but most a re
polymodal, responding to
noxious, t hermal, me chanical
and chemical stimuli.
Figure 3 | Neuroimmune enhancement of noci cept ion. Soluble mediators released by reactive immunocompetentcells in the central nervous system diffuse and bind to receptors on presynaptic and postsynaptic terminals in thespinaldorsal horn to modulate excitatory and inhibitory synaptic transmission, result ing in nociceptive hypersensit ivity.Tumour necrosis factor (TNF), interleukin-1β (IL-1β), CC-chemokine ligand 2 (CCL2), reactive oxygen species (ROS) andinterferon-γ (IFNγ) increase glutamate (Glu) release from central terminals, part ly due to the activationof transientreceptor potential channel subtypes (TRPV1 and TRPA1), and functional coupling between interleukin-1 receptor 1(IL-1R1) and presynaptic ionot ropic glutamate receptors (NMDAR). TNF, IL-1β, IL-6 and ROS decrease GABA(γ-aminobutyric acid) and glycine (Gly) release by inhibitory interneurons. IL-1β and CCL2 also increase AMPA
(α-amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid) signalling, and TNFR1 signalling increases the expressionof Ca2+-permeable AMPA receptors (AMPARs). TNF increases NMDAR activity through the phosphorylation (P) ofextracellular signal-regulated kinases (ERKs), while IL-17 and ROS induce phosphorylat ion of the NR1 receptor subunitin spinal cord neurons. IL-1β increases the calcium permeability of NMDAR through activation of SRC family kinases andalso via phosphorylation of the NR1, NR2A and NR2B subunits. CXCL1 signalling via CXCR2 induces rapid activation ofneuronal ERK and CREB. Brain-derived neurot rophic factor (BDNF) signall ing via TRKB downregulates thepotassium-chloride cotransporter KCC2, increasing t he intracellular Cl – concentration and weakening the inhibitoryGABA
A and glycine channel hyperpolarization of second-order nociceptive projection neurons. Prostaglandin E2 (PGE2)
signalling at the EP2 receptor activates protein kinase A (PKA), thereby inhibiting glycinergic neurotransmission viaGlyR3. IL-1R1 signalling reduces neuronal expression of Gprotein-coupled receptor kinase 2 (GRK2), a negativeregulator of G protein-coupled receptors (GPCRs), including chemokine and prostaglandin receptors, leading tosustained neuronal GPCR signalling. TNF and IL-1β downregulate astrocyte expression of the Glu transporters excitatoryamino acid transporter 1 (EAAT1) and EAAT2, leading to enhanced glutamatergic transmission. CCR2, CC-chemokinereceptor 2; GABAR, GABA receptor.
IL-1R1 NMDARTRPV1TRPA1
Second-order painprojection neuron
First-orderneuron
Inhibitoryinterneuron
TNFR1
CCR2
Ca2+
Ca2+
AMPAR
CXCL1
TRKB
BDNF
NMDARGlyR3GABAR
EP2
PGE2
IL-1R1
NR2B
CCL2
REVIEWS
224 | APRIL 2014 | VOLUME 14 www.nature.com/reviews/immunol
8/15/2019 Pathological Pain and the Neuroimmune Interface - Nri3621
http://slidepdf.com/reader/full/pathological-pain-and-the-neuroimmune-interface-nri3621 9/15
Lamina I neuron s
The most s uperficial aspe ct
of the sp inal dorsal horn
fromwhich second-order
nociceptive projection
neuronsoriginate.
Reversal poten tial
The membrane potential at
which chemical and electrical
drive are eq ual and oppo site,
such that there is no ne t flow
of ions across the me mbrane.
The direction of flow reverses
above a nd be low this potential.
Diminished inhibitory synaptic transmission. The noci-
ceptive pathway is regulateat multiple levels through
numerous inhibitory systems. Interestingly, a reuctionor loss of inhibitory synaptic transmission (known as
isinhibition) in the spinal corpain circuit has also
been implicatein the genesis of central sensitizationanchronic pain15. TNF, IL-1β, IL-6, CCL2, IFNγ anROS ecrease inhibitory signalling in the spinal or-
sal horn by reucing the release of GABA anglycinefrom interneurons aninhibitory escening projec-tions92,108–110. Such immune meiators also contribute to
isinhibition at the postsynaptic membrane of centralsynapses. BDNF is releaseas a consequence of micro-gliosis an, on activation of the neuronal cognate recep-
tor TRKB (also known as NTRK2), ownregulates theprincipal neuronal potassium-chlorie cotransporter,
KCC2, thereby increasing the intracellular Cl− concen-tration in lamina I neurons38,39. This positive shift of theanion reversal pote ntial weakens GABA
A anglycine
channel hyperpolarization, aneven causes GABA-evokeepolarization in a minority of neurons38,39. The
ultimate consequence of suchisinhibition is an increasein nociceptive hypersensitivity, anan unmasking ofresponses to innocuous peripheral inputs38,39,111.
Protective role of central immune signall ingA complex network of regulatory mechanisms activelycontrols central immune signalling after neuronal insult.These mechanisms inclue the prouction of anti-
inflammatory meiators anthe polarization of special-izecells with an anti-inflammatory phenotype to preventuncontrolleinflammation, as well as coorination of
temporal aniverse classic pro-inflammatory mecha-
nisms. An imbalance in such regulatory mechanismsmight contribute to the evelopment of chronic pain,
presenting therapeutic opportunities to enhance neuro-
protection anneuroregeneration while suppressingestructive inflammation.
Protective anti-inflammatory mechanisms and pheno-types. A reactive phenotype is not synonymous witha pro-inflammatory anpro-nociceptive phenotype.
That is,epening on the stimulating signal, there aresubpopulations of reactive immune cells with an anti-inflammatory phenotype. Although the existence of a
parallel anti-inflammatory microglial cell phenotyperemains controversial, these anti-inflammatory popula-
tions inclue alternatively activatemacrophages (also
known as M2 macrophages), anTH2 anTReg cellsthat contribute to the resolution of nociceptive hyper-
sensitivity after nerve injury18,23,26,29,112,113. A hallmark ofsuch anti-inflammatory cell types is their prouction of
anti-inflammatory meiators, such as IL-1Ra, IL-4 anIL-10 in the spinal orsal horn. The factors riving therecruitment anifferentiation of such anti-inflamma-
tory phenotypes are not well unerstoo. Nociceptivehypersensitivity associatewith spinal gliosis is attenu-
ateby intrathecal aministration of IL-1Ra, elevationof spinal IL-10 levels, anby systemic aministration ofglatiramer acetate, which increases expression of IL-4+
anIL-10+ Tcells in the spinal orsal horn8,26,114,115 .
Asie from the effects of IL-1Ra on excitatory post-
synaptic current (EPSC) frequency anNR1 subunit
phosphorylation, it remains to be shown whether otheranti-inflammatory cytokines irectly regulate central
sensitization96,101. However, the anti-nociceptive effects
may be inirect, as IL-4 anIL-10 inhibit the synthesisof pro-inflammatory cytokines anchemotactic factors
by microglia anTcells, anregulate cell phenotype
anthe expression of MHC classII anco-stimulatorymolecules116,117. In aition to these meiators, cellswith an anti-inflammatory phenotype express enzymes
that promote extracellular matrix repair anMAPKphosphatases, as well as receptors that suppress pro-inflammatory signalling (for example, IL-1R2 anIL-10R). Microglia also express scavenger receptors anco-stimulatory molecules (such as CD86) that can pro-
mote the evelopment of regulatory aaptive immuneresponses18,23,116,118,119 .
Protection mediated by pro-inflammatory mechanisms.The isplay of pro-inflammatory phenotypes by reac-
tive innate anaaptive immune cells is not necessarilysynonymous with nociceptive hypersensitivity antissueestruction; a rapi, well-regulateimmune response to
neuronal insult is important for the regulation of gliosisanclearance of tissue ebris to promote neuroregen-
eration. TNF seems to have a more prominent role thanIL-1β in promoting neuronal regeneration in the CNS,whereas both cytokines have crucial roles in peripheral
neuronal regeneration120,121. In a moel of nitric oxie-inuceneurotoxicity, neuronal celleath anemyeli-nation were increasein TNF-eficient mice relative to
wil-type controls120. Furthermore, although microgliosis
was attenuatewithin 6hours in these mice, it was exac-erbate4ays later. Hence, TNF perse may be requirefor the control of seconary amage, or the sequence of
the early reactive cascae in general may be crucial forsuch control. In aition to temporal action, several other
factors may influence neuroprotection in general, inclu-
ing the receptor subtype involve(for example, TNFR1or TNFR2, IL-1R1 or IL-1R2) another stimulatingsignals that accompany insult etection63,64,67,122.
Finally, after neuronal insult, reactive microgliaphagocytose apoptotic cells anebris, aneliminate thesource of DAMPs, leaving healthy tissue intact. Such a
nuanceanregulatereactive response may be coor-
inatethough microglial cell recognition of particu-
lar inhibitory molecules that are expresseby healthy
cells within the CNS. The molecules involvein inhib-iting innate immune cells may be humoral (for exam-
ple, semaphorin) or membrane-boun(for example,CD22, CD47, CD200 anCD200R)36,37. Cells that have
unergone apoptosis lose expression of these inhibitorymolecules anincrease their expression of ‘altere-selfmolecular patterns’ (for example, nucleic acis, sugars,
oxiizelow-ensity lipoproteins analteremembraneelectrical charge), allowing reactive microglia to selec-
tively phagocytose such cells37. These mechanisms havenot been irectly implicatein nerve injury-inucecentral immune signalling, but may be ysregulatein
persistentpain.
REVIEWS
NATURE REVIEWS | IMMUNOLOGY VOLUME 14 | APRIL 2014 | 225
8/15/2019 Pathological Pain and the Neuroimmune Interface - Nri3621
http://slidepdf.com/reader/full/pathological-pain-and-the-neuroimmune-interface-nri3621 10/15
Anti-allodynic and
anti-hyperalgesic
Compounds that op pose
allodynia a nd hyperalgesia
torestore basal sensory
thresholds.
The neuroimmune interf ace and pain controlThe funamental role of neurons in neuropathic pain isunispute. However, the strongest pain managementstrategies currently in use focus on suppressing aberrant
neuronal activity anlack suitable efficacy123. Given thekey role of the neuroimmune interface in persistent pain,there is interest in targeting these mechanisms for pain
management. There are several strategies that coulbeuseto target the neuroimmune interface: first,irect inhi-
bition of local pro-inflammatory signalling; secon, stimu-
lation of local protective anti-inflammatory mechanisms;thir, inhibition of specific immune meiators; anfinally,
antagonism of specific cytokine or chemokine receptors.Cytokines anchemokines in the CNS have been
targetepreclinically using the TNF inhibitor etaner-cept anIL-1Ra to successfully attenuate nociceptivehypersensitivity8,124. However, clinical translation of
such therapies may be limiteby potential isruptionof the beneficial neuroprotective anneuroregenerative
effects of TNF anIL-1, anby the inability of such mol-ecules to penetrate the bloo–CNS barrier. Although thebeneficial effects of pro-inflammatory meiators coulbe left intact by selectively targeting receptor subtypes
that meiate amaging pro-inflammatory processes
(for example, TNFR1 or IL-1R1), such approaches havenot yet been emonstratefor pain, but are likely to betoo specific to aress the wiespreaaaptations an
possible reunancy of cytokines anpain process-ing pathways33. Hence, the first two cellular approachespresent the greatest potential for clinical translation an
are focuseon below (summarizein TABLE1).
Inhibition of pro-inflammatory signalling at the neuro-
immune interface. Extensive preclinical stuies of theanti-inflammatory rugs minocycline, propentofyl-
line, ibuilast (MN-166; MeiciNova) anmethotrex-ate (which inhibit gliosis anTcell activation through
various mechanisms; TABLE1), have shown anti-allodynic
and anti-hyperalgesic efficacy in neuropathic pain moels,however, some of these rugs have hamixeclinical
success23,42,125–129. Ibuilast has shown signs of efficacy inneuropathic pain anmultiple sclerosis126. Ibuilast is in
PhaseII of clinical evelopment for meication overuseheaache (ClinicalTrials.gov ientifier: NCT01317992)anprogressive multiple sclerosis with neuropathic
pain as a seconary enpoint (NCT01982942).
Table 1 | Modulators of the neuroimmune interface
Drug name Cellular targets Mechanism of act ion Clinical use
Amitriptyline Microglia Disrupts TLR4 signalling by binding to MD2 Depression
ATL313 (Santen Pharmaceutical) Microglia and astrocytes • Adenosine A2A
receptor agonist• PKA and PKC activation
NA
BAY 60–6583 (Bayer HealthCare) Microglia and astrocytes Adenosine A2B
receptor agonist NA
Ceftriaxone Astrocytes Increases EAAT2 expression by inhibit ing NF-κ B activity • Bacterial meningitis• Lyme disease
Dilmapimod Microglia Selective p38 MAPK inhibition NA
FP-1 Microglia TLR4 antagonist NA
Glatiramer acetate Tcells Promotes generation of anti-inflammatory Tcell phenotypes Multiple sclerosis
Ibudilast(MN-166; MediciNova)
Microglia, astrocytesand Tcells
Non-selective phosphodiesterase inhibitor • Asthma• Post-stroke dizziness
Methotrexate Tcells Suppresses expression of cell adhesion molecules • Breast cancer• Rheumatoid arthrit is
Minocycline Microglia, Tcells andneurons
• Inhibits NF-κ B translocation to the nucleus• Inhibits NFAT1
Acne vulgaris
Paroxetine Microglia P2X4R antagonist Depression
Propentofylline(Aventis Pharma)
Microglia, astrocytesand neurons
• Inhibits cAMP and cGMP phosphodiesterases• Adenosine reuptake inhibitor
Ischaemic stroke
Resolvin D1(ResolvyxPharmaceuticals)
Microglia and neurons • Attenuates pro-inflammatory cytokine release• Inhibits TRPV1• Reverses NMDAR subunit phosphorylation
NA
Resolvin E1(ResolvyxPharmaceuticals)
Microglia and neurons • Attenuates pro-inflammatory cytokine release• Inhibits TRPV1• Attenuates glutamate release• Reverses NMDAR subunit phosphorylation
NA
Rifampin Microglia Disrupts TLR4 signalling by binding to MD2 Tuberculosis
(+)-naloxone Microglia Disrupts TLR4 signalling by binding to MD2 NA
(+)-naltrexone Microglia Disrupts TLR4 signalling by binding to MD2 NA
A2A
, adenosine receptor 2A; A2B
, adenosine receptor 2B; cAMP, cyclic AMP; cGMP, cyclic GMP; EAAT2, excitatory amino acid t ransporter 2; MAPK,mitogen-activated protein kinase; MD2, myeloid differentiation protein 2; NA, not applicable (no current clinical application); NFAT1, nuclear factor of activatedTcells 1; NF-κ B, nuclear factor-κ B; NMDAR, ionotropic glutamate receptor; P2X4R, P2X purinoceptor 4; PKA, protein kinase A; PKC, protein kinase C; TLR4, Toll-likereceptor 4; TRPV1, transient receptor potential cation channel subfamily V member 1
REVIEWS
226 | APRIL 2014 | VOLUME 14 www.nature.com/reviews/immunol
8/15/2019 Pathological Pain and the Neuroimmune Interface - Nri3621
http://slidepdf.com/reader/full/pathological-pain-and-the-neuroimmune-interface-nri3621 11/15
RadiculopathyA condition a rising from
acompressed spinal nerve
rootthat is ass ociated with
pain, numbness, tingling or
weakness along the course
of the ne rve.
Carpal tunnel syndrome
A syndrome arising from
compression of the median
nerve — which runs from the
forearm into the palm of the
hand — that is associated with
itching numbness, burning
and /or tingling.
There are several possible reasons for these mixe
results, such as the inherent esign flaws that have beenhighlightefor trials involving propentofylline anminocycline130,131. It is therefore important that prior
failures are taken into consieration anthat a consen-sus is reacheon clinical trial esign for rugs target-
ing the neuroimmune interface. It is also possible thatcurrent neuroimmune moulators retain confoun-ing off-target effects that limit efficacy. For example,
minocycline has been shown to increase the expressionanphosphorylation of Ca2+-permeable AMPA recep-tors in mice, which will oppose anti-alloynic ananti-
hyperalgesic efficacy132. Furthermore, neuroimmune
moulators such as minocycline, propentofylline anibuilast may lack selectivity for specific glial animmune cell phenotypes, leaing to suppression of
neuroprotective anneuroregenerative effects. Theresults of an ear ly stuy suggestethat minocycline
hanon-selective actions on microglial cell subpopu-
lations as, espite attenuating alloynia inucebyintrathecal aministrat ion of HIV-1 gp120 envelopeprotein, minocycline also suppressethe expression
of IL1RN (which encoes IL-1Ra) anIL10 mRNA10.However, only a single stuy to ate has irectly char-acterizethe effect of neuroimmune moulators on
the phenotype of microglia, in which minocyclineselectively inhibiteexpression of M1, but not M2,
microglia markers in the mutant superoxie is-
mutase1 (SOD1G93A) mouse moel of amyotrophiclateral sclerosis (ALS)133. Hence, it is necessary that
further stuies are unertaken to efine the selectivityof phenotype-specific effects of neuroimmune mou-
lators, as broa-spectrum inhibition may be etrimen-tal to recovery.
The ambitious but attractive, approach is to antago-
nize specific stimulatory signals that rive estructiveanpro-nociceptive processes, while simultaneously
allowing for the coorination of a normal immuneresponse to insult via anti-inflammatory anregulatepro-inflammatory phenotypes. Preclinical ata sug-
gest that the TLR4 anpurinergic receptor signalling
cascaes in microglia may fulfil such criteria59,71.
Several novel TLR4 antagonists have shown efficacy
in preclinical neuropathic pain moels, incluingrifampin, FP-1 anthe opioireceptor-inactive isomers
(+)-naloxone an(+)-naltrexone79,80,134–136. In aition,
TLR4 antagonism may be exploiteto improve theefficacy anaverse effect profile of opiois (BOX3 ).
Given the observepreclinical efficacy, the purinergic
receptors P2X4R or P2X
7R are also potential therapeu-
tic targets for neuropathic pain22,40,63,64. Interestingly,some antiepressants current ly inicatefor neuro-
pathic pain, such as amitriptyline anparoxetine, pos-sess significant TLR4 anP2X
4R inhibitory activity,
respectively137,138. An alternative irect approach may
be to target ownstream signalling pathways, such asp38 MAPK, which rives microglia towars a reac-
tive state. A recent trial emonstrateoral analgesicefficacy for a selective p38 inhibitor, ilmapimo(SB681323; GlaxoSmithKline), in patients with nerve
trauma, radiculopathy or carpal tunnel syndrome139.Pro-resolution lipi meiators, such as the
resolvins, protectins an lipoxins, are emerging aspotent ial therapies that have irect effects on patho-logical neuroimmune transmission. Biosynthesize
uring the resolution of acute inflammation, suchmeiators were or iginally isolatefrom exuates in
both roents anhumans140. Pro-resolution meia-tors signal at their cognate GPCRs, such as CHEMR23(also known as CMKLR1; which is activate by
resolvin E1) anN-formyl peptie receptor 2 (FPR2;also known as ALX) which is activateby resolvin D1anlipoxin A4), anare wiely expresseby neurons,
glia anperipheral immune cells140. These meiators
have markeeffects on nociceptive hypersensitivityin iverse pain moels, not by moifying basal pain
threshols like analgesics, but by restoring normal sen-
sitivity through moification of aberrant neuroimmunetransmission140,141.
Stimulation of anti-inflammatory signalling at theneuroimmune interface. There are several potentialtherapeutics that may attenuate pathological neuro-
immune signalling by stimulating anti-inflammatorymechanisms to restore homeostasis in the spinal orsalhorn microenvironment. The aenosine GPCRs A
2A
anA2B
are expresseby peripheral immune cells anglia, anpharmacologically targeting these receptors
with a single intrathecal injection of specific agonists
reverses establisheperipheral nerve injury-nociceptivehypersensitivity for more than 4weeks114,115. This thera-
peutic effect is epenent on the activation of proteinkinase A (PKA) anprotein kinase C (PKC), leaing
to elevateIL-10 anecreaseTNF levels. Withoutexcluing a contribution from recruiteor other resi-ent cells, these pathways were specifically ientifie
in resient microglia anastrocytes. In aition, ceftri-axone anglatiramer acetate may restore homeostasis
either by normalizing astrocyte expression of EAAT2or by increasing the recruitment of IL-4-proucinganIL-10-proucing Tcells to the spinal orsal horn,
respectively26,107.
Box 3 | Opioids and central immune signall ing
Opioids remain the gold standard therapy for acute and chronic pain. However, their
clinical use is limit ed by issues with tolerance, paradoxical hyperalgesia and their
abuse potential. Although these adverse effects can be partly explained by neuronal
mechanisms, the emerging role of central immune signalling is revolut ionizing opioid
pharmacology136,174. In addit ion to stereoselectively signalling at classical opioid
receptors, morphine is now known to non-stereoselectively signal at Toll- like receptor 4
(TLR4) by binding t o myeloid differentiation factor 2 (MD2)136,174,17
. Hence, in addit ion tobeing activated by opioid receptor active (-)-isomers, TLR4 is also non-stereoselectively
activated by opioid receptor inactive isomers, such as (+)-morphine and the metabolite
morphine-3-glucuronide, and may be selectively antagonized by opioid receptor
inactive (+)-naloxone and (+)-nalt rexone80,136,174. The initiation of central immune
signalling by TLR4 activation has marked consequences for opioid pharmacodynamics,
including opposit ion of analgesia, probably by induction of central sensit ization, and
also opioid reward, craving, reinstatement and withdrawal174,176. A recent study
has also shown that µ-opioid receptor signalling on microglia induced brain-derived
neurotrophic factor (BDNF) release, downregulating the potassium-chloride
cotransporter KCC2 and disrupting the anion reversal potential177. Such alterations
were found to contribute to hyperalgesia, but not tolerance.
REVIEWS
NATURE REVIEWS | IMMUNOLOGY VOLUME 14 | APRIL 2014 | 227
8/15/2019 Pathological Pain and the Neuroimmune Interface - Nri3621
http://slidepdf.com/reader/full/pathological-pain-and-the-neuroimmune-interface-nri3621 12/15
Complex regional pain
syndrome
An idiopathic chronic pain
condition that usually affects
an a rm or leg and typically
develops after an injury,
surgery, stroke or hea rt atta ck,
but the pain is out of
proportion to the se verity of
the initial injury, if any.
Capsaicin
The active component of chilli
pep pers. It selectively binds to
transient receptor pote ntial
cat ion chann el subfamily V
me mbe r 1 (TRPV1) on
nociceptive a nd heat-sensing
neurons.
Postherp etic neuralgia
Neuropathic pain that occurs
in some patients following
infection with t he varicella
zoster virus, predominantlyaffecting the face.
Peripheral benzodiazepine
binding site
GABAA receptors in the central
nervous system (CNS)
represent the primary site of
action for benzodiazepines,
such as diazepam. The
peripheral benzodiazepine
binding site was originally
discovered in the periphery
asecondary binding site, but
has since b ee n identified in
the CNS.
Anti-inflammatory cytokine gene therapy with
either nakeDNA, or a range of vectors, is yet another
approach142. IL-4 anIL-10 gene therapies have proveneffective in moels of peripheral inflammation annerve injury, spinal corinjury, paclitaxel neuropathy
anexperimental encephalomyelitis42,142. Such efficacyis correlatewith reucelevels of phosphorylatep38, TNF, IL-1β anPGE2 in spinal microglia, as well
as ecreaseGFAP expression by astrocytes. Avoiingsome of the safety issues associatewith viral vectors,long-term reversal of peripheral nerve injury-inuce
nociceptive hypersensitivity has been achieveusingsynthetic polymer vectors to encapsulate anreleasethe IL-10 transgene upon int rathecal injection142,143.
Clinical evidence for the neuroimmune interf aceSeveral lines of correlative aninirect evience existin support of glial cell involvement in clinical chronicpain conitions. In a post-mortem stuy, astrocyte but
not microglial cell activation markers were upregulatein the orsal spinal cors of patients with HIV who ha
been experiencing chronic pain, anastrocytes fromthese iniviuals also showean increaseensity anhypertrophic morphology144. The patients also isplaye
increasephosphorylation of ERK, p38 anJNK, as wellas elevatelevels of TNF anIL-1β, in the orsal spinal
cor144. Another post-mortem stuy reporteincreasemicrogliosis anastrogliosis in the spinal corgrey matterof a patient with longstaning complex regional pain syn-
drome, although this stuy may have been confounebythe effects of prolongeopioiuse by the patient145 (BOX3).However, these finings are supporteby observations
that the levels of IL-1β anIL-6 are increasein the cer-
ebrospinal fluiof some patients with complex regionalpain synrome146. Clearly, there is a paucity of human
ata on pathological anpharmacological glial responses,
as highlighteaniscusseby several groups41,129,130.Eneavours to characterize the functional ifferences
between roent anhuman glia are of paramount
importance to inform translational pharmacology.P2X7R is expresseby all myeloicells, inclu-
ing microglia, ansingle nucleotie polymorphisms in
P2RX7 that affect pore formation anchannel functionare associatewith variability in chronic pain in two clini-cal populations62. Hyper- or hypo-functional variants
were associatewith increaseor ecreasepain ratings,respectively, in cohorts of patients with post-mastectomy
anosteoarthritis pain compareto pain-free controls62.
However, as impaireP2X7R function is also associatewith reucebone mineral content anensity in mice,
ifferences in pathology might also explain the correlationbetween osteoarthritis pain anP2RX7 polymorphism147.
In a recent stuy in healthy volunteers, intravenouspretreatment with a low ose of enotoxin was shownto enhance flare, hyperalgesia analloynia inuce
by intraermal capsaicin, ancorrelate with increaseplasma levels of IL-6 (REF.148). The observelarge effect
size anthe fact that alloynia anhyperalgesia are cen-trally meiate, suggests the inuction of central sensi-tization, probably ue to an inirect effect of enotoxin
meiatethrough a peripheral cytokine cascae.
Asescribeabove, microglia have been pharmaco-
logically targetein clinical chronic pain populations. A
recent stuy showethat minocycline attenuatehyperal-gesia in a small cohort of patients with sciatica128. Ibuilast
also showesigns of efficacy in relieving pain associate
with painful iabetic neuropathy ancomplex regionalpain synrome126. In contrast to these promising stu-
ies, propentofylline faileto improve self-reportepain
scores, comparewith placebo, in patients with posther-
petic neuralgia129. Trials such as these have been unertakenon the assumption that possible functional ifferences
between human anroent glia woulnot limit the effi-cacy ofrugs such as propentofylline in attenuating gliosisin humans. In aition to this assumption, severalesign
flaws were inherent in the propentofylline trial, incluingselection of a pain synrome for which no ata exist to
support glial cell involvement, ana lack of confirmationof whether the rug reachetherapeutic concentrationsat the target site. Furthermore, as preclinical stuies ini-
cate that it is easier to prevent than reverse neuropathicpain, propentofylline osing may have been prematurely
concluebefore reversal of long-staning pain coulhave been achieve130. The CC-chemokine receptor 2(CCR2) antagonist AZD2423 (AstraZeneca) showea
trentowars reuction in paroxysmal pain anpares-thesia anysesthesia, suggesting efficacy for some sen-
sory components of pain149. As with many clinical trialsfor pain, intra- aninter-iniviual variability was high,which may be overcome by enriching for a specific subset
of patients. Furthermore, target site efficacy was not evalu-ate. These issues further highlight the neeto evelopmethos to enableetection of glial responses inhumans.
Imaging may be one approach to etect real-time
gliosis in patients with chronic pain. Although not com-pletely specific for these cells, the peripheral b enzodiaz-
epine binding site is expresseby reactive microglia an
allows them to be imagein magnetic resonance imagingscans using the selective raioligan[11C](R)-PK11195.
Bining of [11C](R)-PK11195 to microglia in the human
thalamus is increasefor many years after peripheralnerve injury150, however, further investigation is requireto valiate these finings.
Finally, it is worth noting that neuropathic pain is oftencomorbiwithiseases in which ysregulation of centralimmune signalling is better establishe, such as multiple
sclerosis anALS151,152. In aition, epression, anxietyanrug abuse — common comorbiities of chronic pain
— have a central immune basis153. These converging lines
of evience provie further inirect support forysfunc-tional central immune signalling as a major contributor
to chronic pain in clinical populations.
Conclusions and future directionsMore than two ecaes of research has seen the accumu-lation of a wealth of ata supporting a major role for cen-
tral immune signalling in preclinical moels of pain, withmicroglia anastrocytes being among the best character-
izemembers of the neuroimmune interface. However,future stuies are likely to uncover prominent roles forother resient aninfiltrating immunocompetent cells in
the spinalorsal horn. Although the early stuy of central
REVIEWS
228 | APRIL 2014 | VOLUME 14 www.nature.com/reviews/immunol
8/15/2019 Pathological Pain and the Neuroimmune Interface - Nri3621
http://slidepdf.com/reader/full/pathological-pain-and-the-neuroimmune-interface-nri3621 13/15
immune signalling focuseon the pro-nociceptive effects
of reactive phenotypes animmune meiators, the fiel
is beginning to appreciate pleiotropic roles for such ‘pro-inflammatory’ phenotypes, in aition to those of special-
izeanti-inflammatory reactive phenotypes. Mirroring
the general trenwithin preclinical pain research, mostinvestigations have exclusively focuseon the contribution
of central immune signalling to the sensory component of
pain. Given that patients with chronic pain experiencemany other symptoms, incluing isability, anxiety,epression, cognitiveysfunction ansleep loss (some of
which can be preclinically moelle), investigation of therespective neuroimmune correlates will yielgreat insight.
The existence anprecise mechanisms of cen-
tral immune signalling in humans have not yet been
conclusively establishe. A consierable challengefor the future is to etermine whether pathological
neuroimmune signalling contributes to chronic pain
in clinical populations. However, clinical tr ials oftherapeutics that target the neuroimmune interface
are a possible approach. A further challenge for rug
evelopment is to integrate the basic scientific ata onnuancecentral immune signalling in orer to evelopagents that normalize pathological neuroimmune
transmission, without altering neuroprotective anneuroregenerative pathways.
1. Maier,S.F., Wiertelak,E.P., Martin,D. &
Watkins,L.R. Interleukin-1 mediates the behavioral
hyperalgesia produced by lithium chloride and
endotoxin. Brain Res. 62 3, 3 21–3 24 (1993).
2. Ferreira,S.H., Lorenzetti,B.B., Bristow,A.F. &
Poole,S. Inte rleukin-1β as a potent hyperalgesic agent
antagonized by a tripeptide analogue. Nature 3 34 ,
698– 700 (1988).
3. Watkins,L.R. etal. Charact erization of cytokine-
induced hyperalgesia. Brain Res. 654 , 15– 26 (19 94 ).
4. Bianchi,M., Sacerdote,P., Ricciardi-Castagnoli,P.,
Mantegazza,P. & Pane rai,A.E. Central e ffects of
tumor necrosis factor alpha and interleukin-1 alpha
onnociceptive thresholds and spontaneous locomotor
activity. Neurosci. Lett. 14 8, 7 6– 80 (1992 ).
5. Watkins,L.R., Maier,S.F. & Goe hler,L.E. Immune
activation: the ro le of pro-inflam mat ory cytokines in
inflammation, illness responses and pathological pain
states. Pain 63, 289 –30 2 (1995).
6. Garrison,C.J., Dougherty,P.M., Kajander,K.C. &
Carlton,S.M. Staining of glial fibrillary acidic protein
(GFAP) in lumb ar spinal cord increases following a
sciatic nerve constr iction injury. Brain Res. 56 5, 1 –7
(1991).
7. Svensson,M. etal. The response of central glia to
peripheral nerve injury. Brain Res. Bull. 30 , 49 9– 50 6
(1993).
8. Watkins,L.R., Martin,D., Ulrich,P., Tracey,K.J. &
Maier,S.F. Evidence for the involveme nt of spina l cord
glia in subcutaneous formalin induced hyperalgesia inthe rat . Pain 71, 225 –23 5 (1997).
9. Meller,S.T., Dykstr a,C., Grzybycki,D., Murp hy,S. &
Gebhart,G.F. The possible role of glia in
nociceptiveprocessing and hyperalgesia in the spinal
cord of the rat . Neuropharmacology 33, 1 471– 147 8
(1994).
10. Ledeboer,A. etal. Minocycline att enuate s me chanical
allodynia and proinflammatory cytokine expression in
rat mode ls of pain facilitation. Pain 115 , 71– 83 (20 05 ).
11. Milligan,E.D. etal. Intra theca l HIV-1 en velope
glycoprotein gp120 induces enha nced pain states
mediated by spinal cord proinflammatory cytokines.
J.Neurosci. 21, 28 08– 2819 (2001 ).
The firs t dem onstrat ion that spinal microgliosis
issufficient t o induce no cicept ive hype rse nsitivity
via pro duction and release of pro-inflamma tory
cytokines.
12. Basbaum,A.I., Bautista,D.M., Scherrer,G. &
Julius,D. Cellular and molecular mechanisms of pain.
Cell 13 9, 267 –28 4 (2009).13. Ossipov,M.H., Dussor,G.O. & Porreca,F. Central
modulation of pain. J.Clin. Invest . 12 0, 3 779 –3 787
(2010).
14. Pizzo,P.A. & Clar k,N.M. Alleviating suffering
101-pain relief in the United States. N.Engl. J.Med.
366 , 197–199 (2012).
15. Latremoliere,A. & Woolf,C.J. Central sensitization:
agenerator of pain hypersensitivity by central neural
plasticity. J.Pain 10, 895 –92 6 (2009).
An excellent review of the neuronal changes
implicate d in the creat ion and maintenance of
exaggera ted pain s t a t es .
16. Scholz,J. & Woolf,C.J. The neuropa thic pain triad:
neurons, immune cells and glia. Na ture Neurosci. 10,
1361–1 368 (2007).
17. Araque,A. & Navarre te,M. Glial cells in
neuronalnetwork function. Phil. Trans. R.Soc. B
3 6 5 ,2375– 2381 (2010).
18. Hanisch,U.K. Functional diversity of microglia -
howheterogeneous a re they to be gin with?
Front. Cell Neurosci. 7, 65 (2013).
19. Nimmerjahn,A., Kirchhoff,F. & Helmchen ,F. Res ting
microglial cells are highly dynamic surveillantsof brain
paren chyma in vivo. Science 3 08 ,1314–1318 (2005).
20. Kettenmann,H., Hanisch,U.K., Noda,M. &
Ver khra tsky,A. Physiology of microglia. Physiol. Rev.
91, 461– 553 (2011).
21. Sofroniew,M.V. Mo lecular dissection of re active
astr ogliosis and glial scar format ion. Trends Neurosc i.
32 , 638–6 47 (2009).
22. Ulmann,L. etal. Up-regulation of P2X4 receptors in
spinal microglia after peripheral nerve injury mediates
BDNF release a nd neuropa thic pain. J.Neurosci. 28 ,
11263–11268 (2008) .
23. Grace,P.M., Rolan,P.E. & Hutchinson,M.R.
Peripheral immune contributions to the maintenance
of central glial activation under lying neuropa thic pain.
Brain Behav. Immun. 25, 1322–1332 (2011).
24. Zhang,J. etal. Express ion of CCR2 in both
residentand bone marrow-derived microglia plays
acritical role in neuropa thic pain. J.Neurosci. 27,
12396 –1240 6 (2007) .
25. Costigan,M. eta l. T-cell infiltra tion a nd sign aling
inthe a dult dorsal spinal cord is a major contributor
toneurop ath ic pain-like hypersens itivity. J.Neurosci.
29 , 14415–14 422 (2009).
26. Leger,T., Grist ,J., D’Acquisto,F., Clar k,A.K. &
Malcangio,M. Glatiramer acetate attenuatesneuropathic allodynia through modulation of adaptive
immune cells. J.Neuroimmunol. 234, 19–26 (2011).
27. Meng,X. etal. Spinal interleukin-17 promotes thermal
hyperalgesia and NM DA NR1 phosp horylation in an
inflammatory pain rat model. Pain 154 , 294 –3 05
(2013).
28 . Tsuda ,M. eta l. IFNγ receptor signaling mediates
spinal microglia a ctivation dr iving neuropa thic pain.
Proc. Natl Acad. Sci. USA 10 6, 80 32 –8 03 7 (200 9).
29. Austin,P.J., Kim,C.F., Perer a,C.J. & Moalem-
Taylor,G. Regulatory Tcells attenua te
neuropathicpain following per ipheral n erve injury
an dexperimental autoimmune neuritis. Pain 153 ,
1916–1931 (2012) .
30 . Taoka,Y. e tal. Role of neu trophils in spinal cord injury
in the rat . Neuroscience 79 , 1177– 1182 (199 7).
31. Sweitzer,S.M., Hickey,W.F., Ru tkowski,M.D.,
Pahl,J.L. & DeLeo,J.A. Focal per ipheral ne rve injury
induces leukocyte trafficking into the centra l nervous
system: potential relationship to neuropathic pain.Pain 100, 163 –170 (200 2).
32. Kwok,Y.H. etal. TLR 2 and 4 responsiveness from
isolated peripheral blood mononuclear cells from rats
and hum ans a s potent ial chronic pain biomarkers.
PLoS ONE 8, e7 77 99 (201 3).
33. Grace,P.M. etal. Harnessing pain heteroge neity
an dRNA transcriptome to identify blood-based
painbiomarkers: a novel correlational study design and
bioinformatics approach in a gra ded chronic constriction
injury model. J.Neurochem. 12 2, 9 76–99 4 (2012).
34. Kwok,Y.H., Hutchinson,M.R., Gentga ll,M.G. &
Rolan,P.E. Increased responsiveness of peripheral
blood mon onuclear cells to invitro TLR 2, 4 and 7
ligand stimulation in chronic pain patient s.
PLoS ONE 7, e4 42 32 (201 2).
35. Hutchinson,M.R., La Vincente,S.F. & Som ogyi,A.A.
In vitro op ioid induced proliferat ion of periphera l
blood immune cells correlat es with invivo cold pre ssor
pain tolerance in humans: a biological marker of pain
tolerance. Pain 110, 7 51–7 55 (2004).
36. Tian,L., Ra uvala,H. & Gahmberg,C.G. Neuronal
regulation of immune responses in the central
nervous system. Trends Immunol. 3 0, 9 1– 99
(2009) .
37. Hoarau,J.J. etal. Activation a nd cont rol of CNS
innate immune responses in health and diseases: a
balancing act finely tuned by neuroimmune regulators
(NIReg). CNS Neurol. Disord. Drug Targ ets 10 , 25 –4 3
(2011).
38. Coull,J.A. etal. Trans-synapt ic shift in anion gra dient
in spinal lamina I neurons as a mechanism of
neuropathic pain. Nature 42 4, 93 8–9 42 (200 3).
39. Coull,J.A. etal. BDNF from microglia ca uses t he shift
in neuronal anion gradient underlying neuropathic
pain. Nature 438, 1017– 1021 (2005 ).
The firs t re port to identify a m echanism for
glial-mediated enhancement of pain signalling.
40 . Tsuda,M. etal . P2X4 receptors induced in spinal
microglia ga te ta ctile a llodynia after nerve injury.
Nature 424 , 77 8–783 (2003) .
41. Ji,R.R., Berta,T. & Nederga ard,M. Glia a nd pa in:
Ischronic pain a gliopathy? Pain 154 (Suppl. 1),
10–28 (2013).
42. Milligan,E.D. & Watkins,L.R. Pathological and
prote ctive roles o f glia in chronic pain. Nat ure Rev.
Neurosci. 10, 2 3–3 6 (200 9).
43. Kim,D. etal. A critical role of toll-like re ceptor 2
innerve injury-induced spinal cord glial cellactivationand pain hyperse nsitivity. J.Biol. Chem.
282 , 14975 –1498 3 (2007) .
44. Wen,Y.R. etal. Nerve conduction blockade in
th esciatic nerve prevents bu t does not reverse the
activation of p38 mitogen-activated protein kinase in
spinal microglia in the rat spared nerve injury model.
Anesthesiology 107, 312–321 (2007).
45. Suter,M.R., Berta,T., Ga o,Y.J., Decosterd,I. &
Ji,R.R. Large A-fiber activity is required for
microglialproliferation and p38 MAPK
activationinthe spinal cord: differen t effects of
resinifera toxin and bupivacaine on s pinal microglial
changes after spa red nerve injury. Mol. Pain 5, 5 3
(2009).
46. Kawasaki,Y. e tal. Distinct roles of mat rix
metalloproteases in the early- and late-phase
development of neuropathic pain. Nature Med. 1 4,
331–33 6 (2008).
47. Calvo,M. eta l. Neuregulin-ErbB signaling promo tes
microglial proliferation and chemotaxis contributingtomicrogliosis and p ain after p eriphera l nerve injury.
J.Neurosci. 30, 54 37– 545 0 (2010).
48. Abbadie,C. etal. Impaired neuropathic pain responses
in mice lacking the chem okine receptor CCR2.
Proc. Natl Acad. Sci. USA 100 , 794 7– 795 2 (200 3).
49 . Van Stee nwinckel,J. etal. CCL2 re leased from
neuro nal synaptic vesicles in the sp inal cord is a
major mediator of local inflammation and pain after
per ipheral nerve injury. J.Neurosci . 31, 5865–5875
(2011).
50. Dansereau,M.A. eta l. Spinal CCL2
pronociceptiveaction is no longer e ffective in CCR2
receptor antagonist-treated rats. J.Neurochem. 106 ,
757–7 69 (2008).
51. Clark,A.K. etal. Inhibition of spinal microglial
cathepsin S for the reversal of neuropathic pain.
Proc.Natl Acad. Sci. USA 104, 10655–10660
(2007).
REVIEWS
NATURE REVIEWS | IMMUNOLOGY VOLUME 14 | APRIL 2014 | 229
8/15/2019 Pathological Pain and the Neuroimmune Interface - Nri3621
http://slidepdf.com/reader/full/pathological-pain-and-the-neuroimmune-interface-nri3621 14/15
52. Milligan,E.D. etal. Evidence that exogenous and
endogenous fractalkine can induce spinal nociceptive
facilitat ion in ra ts. Eur. J.Neurosci . 20, 2294–2302
(2004).
53. Staniland,A.A. etal. Reduced inflamma tory and
neuropathic pain and decreased spinal microglial
respon se in fractalkine recept or (CX3CR1) knockout
mice. J.Neurochem. 114, 1143 –1157 (2010).
54. Clark,A.K., Wodarski,R., Guida,F., Sas so,O. &
Malcangio,M. Cathepsin S release from primary
cultured microglia is regulated by the P2X7 receptor.
Glia 58, 1 710–1 726 (2010).55. Gao,Y.J. & Ji,R.R. Chemokines, ne urona l-glial
interactions, and central processing of neuropathic
pain. Pharmacol. Ther. 126, 56–68 (2010).
56. Wolf,Y., Yon a ,S., Kim,K.W. & Jung,S. M icroglia,
seen from the CX3CR1 angle. Front. Cell Neurosci.
7, 26 (2013 ).
57. Zhao,P., Waxman,S.G. & Hains,B.C. Modulation
of thalamic nociceptive processing after spinal cord
injury through re mote activation of thalamic microglia
by cysteine cysteine chemokine ligand 21. J.Neurosci.
27 , 8893 –8902 (2007) .
58. Biber,K. etal. Neuronal CCL21 up-regulates
microglia P2X4 expression and initiates
neuropathicpain development. EMBO J. 30 ,
1864– 1873 (2011).
59. Inoue,K. & Tsud a,M. Purinergic systems, neuropathic
pain and th e role of microglia. Exp. Neurol. 23 4,
293–3 01 (2012).
A comprehensive review of the role of purinergic
receptor signalling in pain.
60. Friedle,S.A., Curet,M.A. & Watt ers,J.J.
Recentpatents on novel P2X7 receptor antagonists
and their potential for reducing central nervous
system inflam mat ion. Recent Pa t. CNS Drug Discov.
5, 35– 45 (2010).
61. Bardoni,R., Goldstein,P.A., Lee,C.J., Gu,J.G. &
MacDermott,A.B. ATP P2X
receptors mediate
fastsynaptic transmission in the dorsal horn of
th era tspinal cord. J.Neurosci. 17 , 52 97–53 04
(1997).
62. Sorge,R.E. etal. Genetically determined P2X7
receptor pore formation regulates variability in
chronic pain sensitivity. Nature Med. 1 8, 5 95 –5 99
(2012).
63. He,W.J. etal. Spinal P2X7 receptor mediates
microglia activation-induced neuropathic pain in the
sciatic nerve injury rat model. Behav. Brain Res. 226,
163–1 70 (2012).
64. Chu,Y.X., Zhang,Y., Zha ng,Y.Q. & Zhao,Z.Q.
Involveme nt of microglial P2 X7 re ceptors a nd
downstream signaling pathways in long-term
potentiation of spinal nociceptive responses.
BrainBehav. Immun. 24, 1176–1189 (2010).
65. Yamam oto,K. etal . P2X4 receptors mediate
ATP-induced calcium influx in hum an vascular
endot helial cells. Am. J.Physiol. Hear t Circ. Phys iol.
279 , H285–H292 (2000).
66. Nicke,A. etal. A functional P2 X7 splice varian t with
an alternative transmembrane domain 1 escapes gene
inactivation in P2 X7 knock-out mice. J.Biol. Chem.
284 , 25813–25822 (2009) .
67. Clark,A.K. etal. P2X7-dependent release of
interleukin-1β and nociception in the spinal
cordfollowing lipopolysaccharide. J.Neurosci. 30,
573–5 82 (2010).
68. Kobayashi,K. etal. P2Y12
receptor upregulation
inactivated m icroglia is a gate way of p3 8 signaling
and neuropa thic pain. J.Neurosci . 28, 2892–2902
(2008).
69 . Tozaki-Saitoh ,H. etal . P2Y12
receptors in spinal
microglia are required for neuropathic pain afterperiphe ral nerve injury. J.Neurosci . 28, 4949–4956
(2008).
70. Saijo,K., Crotti,A. & Glass,C.K. Regulation of
microglia activation and deactivation by nuclear
receptors. Glia 61 , 104 –111 (2013 ).
71. Nicotra,L., Loram ,L.C., Watkins,L.R. &
Hutchinson,M.R. Toll-like re cept ors in chron ic pain.
Exp. Neurol. 23 4, 31 6–3 29 (2012 ).
A compre hens ive re view of the role of TLR
signalling in p ain.
72. Kuang,X. etal. Effects of intrat heca l epigallocate chin
gallate, a n inhibitor of Toll-like recep tor 4, on chro nic
neuropathic pain in rats. Eur. J.Pharmacol. 676 ,
51–56 (2012).
73. Ren,P.C. etal. High-mobility group b ox contribute s
to mechanical allodynia and spinal astrocytic
activation in a mouse model of type2 diabetes.
BrainRes. Bull . 88, 3 32– 337 (2012 ).
74 . Tong,W. eta l. Spinal high-mobility group box 1
contributes to mechanical allodynia in a rat model of
bone cancer pain. Biochem. Biophys. Res. Commun.
395 , 572–576 (2010).
75. Hutchinson,M.R. etal. Evidence for a role of heat
shock protein-90 in toll like receptor 4 mediated pain
enhancement in rats . Neuroscience 164 , 1821 –18 32
(2009).
76. Zou,W. eta l. Identification of differentially expressed
proteins in the spinal cord of neuropathic pain models
with P KCγ silence by prote omic ana lysis. Brain Res.
144 0 , 34–46 (2012).77 . Tanga ,F.Y., Nut ile-McMen em y,N. & DeLeo,J.A.
TheCNS role of Toll-like rece pto r 4 in inna te
neuroimmunity and painful neuropathy. Proc. Natl
Acad. Sci. USA 102, 5856–5861 (2005).
78. Cao,L., Tang a,F.Y. & De leo,J.A. The contributing role
of CD14 in toll-like receptor 4 de pende nt neuro pat hic
pain. Neuroscience 158 , 896 –90 3 (2009 ).
79. Bettoni,I. etal. Glial TLR4 rece ptor a s new targe t
totreat neuropathic pain: efficacy of a new receptor
antagonist in a model of peripheral nerve injury in
mice. Glia 56 , 1312 –131 9 (200 8).
80. Hutchinson,M.R. etal. Non-stereoselective
reversalof neuropathic pain by naloxone and
naltrexone : involvement of toll-like r ecepto r 4 (TLR4).
Eur. J.Neurosci. 28, 2 0–2 9 (2008 ).
81. Kropf,P. etal. Toll-like receptor 4 con tribute s to
efficient control of infection with the protozoan
para site Leishma nia major. Infect. Immun. 7 2,
1920–1928 (2004) .
82. Nicotra,L.L. etal. in Australasian Neuroscience
Society Annual Meeting. The role of oestroge nic
innate immune priming in exacerbated female pain.
Abstr. 14 8 (Adelaide, 201 4).
83 . Vonte ll,R. eta l. Toll-like rece ptor 3 e xpre ssion in glia
and ne urons alters in response to white mat ter injury in
preterm infants. Dev. Neurosci. 3 5, 1 30 –13 9 (2013 ).
84. Leow-Dyke,S. etal. Ne urona l Toll-like recepto r 4
signaling induces brain endothelial activation and
neutrophil transmigration in vitro.
J.Neuroinflamma tion 9, 2 30 (201 2).
85. Liu,H.Y. e tal. TLR7 negatively regulates dendrite
outgrowth t hrough t he M yd88 -c-Fos-IL-6 Path way.
J.Neurosci. 33, 114 79– 11493 (2013 ).
86. Acosta,C. & Davies,A. Bacterial lipopolysaccha ride
regulates nociceptin expression in sensory neurons.
J.Neurosci. Res. 86, 107 7–10 86 (2008).
87. Li,Y.Y. e ta l.Src/p38 MAPK pat hway in spinal
microglia is involved in mecha nical allodynia induced
by peri-sciatic administration of recombinant rat
TNF-α. Brain Res. Bull. 96, 5 4– 61 (201 3).
88. Katsura,H. etal. Activation of Src-family kinases
inspinal microglia contributes to mechanical
hypersen sitivity after ne rve injury. J.Neurosci. 26,
8680–8690 (2006) .
89. Zhong,Y. e tal. The d irection of synaptic plasticity
mediated by C-fibers in spinal dorsal horn is decided
bySrc-family kinase s in microglia: the ro le of tumor
necrosis factor-α. Brain Behav. Immun. 24, 8 74– 880
(2010).
90. Milligan,E.D. etal. Intrathecal polymer-based
interleukin-10 gene delivery for neuropathic pain.
Neuron Glia Biol. 2, 293 –3 08 (20 06 ).
91. Chiu,I.M. etal. Bacteria activate sensory neurons
that modulate pa in and inflamma tion. Nature 5 01 ,
52–57 (2013) .
92. Kawasaki,Y., Zhang ,L., Cheng,J.K. & Ji,R.R.
Cytokine mecha nisms of centra l sensitization: distinct
and overlapping role of interleukin-1β, interleukin-6,
and tumor necrosis factor-α in regulating synaptic
an dneurona l activity in the sup erficial spinal cord.
J.Neurosci. 28, 518 9–51 94 (200 8).93. Gao,Y.J. etal. JNK-induced M CP-1 product ion in
spinal cord astrocytes contributes to centra l
sensitization a nd neuropa thic pain. J.Neurosci. 29 ,
4096– 4108 (2009).
94. Zhang,H., Nei,H. & Doughert y,P.M.
Ap3 8mitogen-activated protein kinase-dependent
mecha nism of disinhibition in spinal synaptic
transmission induced by tumor necrosis factor-α.
J.Neurosci. 30, 1284 4–1 285 5 (2010).
95. Nishio,N. etal. Reactive oxygen species enhance
excitatory synaptic transmission in rat spinal dorsal
horn n eurons by activating TRPA1 an d TRPV1
channels . Neuroscience 24 7, 201– 212 (2013 ).
96 . Yan,X. & Weng,H.R. Endogenous inte rleukin-1β in
neuropathic rats enhances glutamate release from
the pr imary afferents in the spinal dorsal horn
through coupling with presynaptic NMDA receptors.
J Biol Chem. 288, 3 054 4–3 055 7 (2013).
97. Medvedeva,Y.V., Kim,M.S. & Usachev,Y.M.
Mechanisms of prolonged presynaptic Ca 2+ signaling
and glutamate release induced by TRPV1 activation in
rat sensory neurons. J.Neurosci. 28, 52 95– 5311
(2008).
98. Park,C.K. etal. Resolving TRPV1- and TNF-α-
mediated spinal cord synaptic plasticity and
inflammatory pain with neuroprotectin D1.
J.Neurosci. 31, 15 072– 150 85 (2011).
99. Stellwagen,D., Beattie,E.C., Seo,J.Y. &
Malenka,R.C. Differential regulation of AMPA
recep tor and GABA recep tor tra fficking by tumo rnecrosis factor-α. J .Neurosci . 25, 3219–3228
(2005).
100. Stellwagen,D. & Malenka,R.C. Synaptic scaling
med iated by glial TNF-α. Nature 440 , 1054–1059
(2006).
101. Zhang,R.X. etal. IL-1ra a lleviates inflamma tory
hyperalgesia through preventing phosphorylation
of NMDA receptor NR-1 sub unit in rats. Pa in 135 ,
232–2 39 (2008).
102. Gao,X., Kim,H.K., Chung,J.M. & Chung,K.
Reactiveoxygen sp ecies (ROS) are involved in
enhancement of NMDA-receptor phosphorylation in
animal models of pain. Pain 131, 262–271 (2007).
103. Viviani,B. etal. Inter leukin-1β enhances NMDA
receptor-mediated intracellular calcium increase
through activation of theSrc family of kinases.
J.Neurosci. 23, 869 2–8 700 (200 3).
104. Zhao,P., Waxman,S.G. & Hains,B.C. Extracellular
signal-regulated kinase-regulated microglia-neuron
signaling by prostaglandin E2 contributes to pain
after spinal cord injury. J.Neurosci . 27, 2357–2368
(2007).
105. Zhang,Z.J., Cao,D.L., Zhang,X., Ji,R.R. & Gao,Y.J.
Chemokine contribution to neuropathic pain:
res pe ctive induction of CXCL1 a nd CXCR2 in spina l
cord astrocytes and neurons. Pain 154 , 2185 –219 7
(2013).
106. Xin,W.J., Weng,H.R. & Dougher ty,P.M. Plasticity
in expression of the glutama te tra nsport ers GLT-1
and GLAST in spinal dorsal horn glial cells following
par tial sciatic nerve ligation. Mol. Pain 5, 1 5
(2009) .
107. Ramos,K.M. etal. Spinal upregulation of glutamate
trans port er GLT-1 by ceftriaxone : thera peut ic efficacy
in a range of experimental nervous system d isorders.
Neuroscience 169, 18 88– 190 0 (2010).
108. Harvey,R.J. etal. GlyR α3: an essential target for
spinal PGE2-mediated inflammatory pain
sensitization. Science 304, 884–887 (2004).
109. Gosselin,R.D. etal. Constitutive expre ssion of CCR2
chemokine re ceptor and inhibition by MCP-1/CCL2 of
GABA-induced current s in spinal cord ne urones.
J.Neurochem. 95 , 1023–10 34 (2005 ).
110. Vikman,K.S., Duggan,A.W. & Siddall,P.J.
Interferon-γ induced disruption of GABAergic inhibition
in the spinal dorsal horn in vivo. Pain 13 3, 1 8– 28
(2007).
111. Keller,A.F., Beggs,S., Salter,M.W. & De Koninck,Y.
Transforma tion of the outp ut of spinal lamina I
neurons after nerve injury and microglia stimulation
underlying neuropathic pain. Mol. Pain 3, 27
(2007).
112. Willemen,H.L. etal. MicroRNA-124 as a novel
treatme nt for persistent hyperalgesia.
J.Neuroinflamm. 9 , 143 (2012 ).
113. Ransohoff,R.M. & Pe rry,V.H. Microglial physiology:
unique stimuli, specialized re sponse s. Annu. Rev.
Immunol. 27 , 119–1 45 (2009).
A comprehensive review of microglia that covers
the diverse phe notypes that a rise in response to
a ra nge of s t imulatory signals .114. Loram,L.C. etal. Intrathecal injection of adenosine
2A receptor agonists reversed neu ropathic allodynia
through prote in kinase (PK)A/PKC signaling.
Brain Behav. Immun. 33 , 112– 12 2 (2013 ).
115. Loram,L.C. etal. Enduring reversal of neuropathic
pain by a single intrathecal injection of adenosine 2A
receptor a gonists: a novel therapy for neuropat hic
pain. J.Neurosci. 29, 14015 –14 025 (2009 ).
116. Sabat ,R. etal. Biology of interleukin-10. Cytokine
Growth Factor Rev. 21, 3 31– 34 4 (2010 ).
117. Luzina,I.G. etal. Regulation of inflamma tion by
interleukin-4: a review of “altern atives”. J.Leukoc. Biol.
92 , 753 –764 (2012) .
118. Ndong,C., Landry,R.P., DeLeo,J.A. &
Romero-Sandoval,E.A. Mitogen activated protein
kinase phosphatase-1 prevents the development of
tactile sensitivity in a rodent model of neuropathic
pain. Mol. Pain 8, 34 (2012).
REVIEWS
230 | APRIL 2014 | VOLUME 14 www.nature.com/reviews/immunol
8/15/2019 Pathological Pain and the Neuroimmune Interface - Nri3621
http://slidepdf.com/reader/full/pathological-pain-and-the-neuroimmune-interface-nri3621 15/15
119. Romero-Sandoval,E.A., Horvath ,R., Landry,R.P. &
DeLeo,J.A. Cannabinoid receptor type2 activation
induces a microglial anti-inflammatory phenotype
a ndredu ces migrat ion via MKP induction and ERK
dephosphorylation. Mol. Pain 5, 2 5 (20 09 ).
12 0. Turrin,N.P. & Rivest ,S. Tumor necrosis factor-α
bu tnot inte rleukin-1β mediates ne uroprotection
inrespo nse t o acute nitric oxide excitotoxicity.
J.Neurosci. 26, 14 3–1 51 (2006).
121. Nadeau,S. etal. Functional recovery after peripheral
nerve injury is dependent on the pro-inflammatory
cytokines IL-1β and TNF: implications for neuro pat hicpain. J.Neurosci. 31, 125 33– 125 42 (2011).
12 2. Fontaine,V. e tal. Neurodegenerative and
neuroprotective effects of tumor necrosis factor
(TNF)in retinal ischemia: oppo site roles of TNF
receptor 1 a nd TNF receptor 2. J. Neurosci. 22,
RC216 (2002).
12 3. Varrassi,G. Management of chronic pain. Foreword.
Clin. Drug Investig. 30 (Suppl. 2), 1 (2010 ).
124. Saito,O. etal. Sp inal glial TLR4-med iated
nociceptionand production of prostaglandin E2
a ndTNF. Br. J .Pharmaco l . 160 , 1754–1764
(2010).
125. Sweitzer,S. & De Leo,J. Prop entofylline: glial
modulation, neuroprotection, and alleviation of
chronic pain. Handb Exp Pharmacol. 2011, 235–250
(2011).
126. Rolan,P., Hutchinson,M. & Johnson,K. Ibudilast:
areview of its ph arm acology, efficacy and safety in
respiratory and neurological disease. Expert Opin.
Pharmacother. 10, 2897–2904 (2009).
12 7. Nikodemova,M., Duncan,I.D. & Watt ers,J.J.
Minocycline exer ts inhibitory effects on multiple
mitogen-activated protein kinases and IκBα
degra dat ion in a st imulus-specific manner in microglia.
J.Neurochem. 96 , 314–3 23 (2006 ).
12 8. Sumracki,N.M. etal. The effects of pregabalin and
the glial attenua tor minocycline on t he response to
intradermal capsaicin in patients with unilateral
sciatica. PLoS ONE 7, e 38 52 5 (201 2).
12 9. Landry,R.P., Jacobs,V.L., Rome ro-Sandoval,E.A. &
DeLeo,J.A. Propent ofylline, a CNS glial mod ulator
does not decrease pain in post-herpetic neuralgia
patients: invitro evidence for differen tial response s
inhuman an d rodent microglia and macrophages.
Exp. Neurol . 234, 3 40– 350 (2012).
13 0. Watkins,L.R. etal. P ropen tofylline, a CNS glial
modulator, does not decrease pain in post-herpetic
neura lgia pa tients: in vitro evidence for differential
responses in human a nd rodent microglia and
macrophages. Exp. Neurol. 2 34 , 351 –35 3 (2012 ).
131. Plane,J.M., Shen,Y., Plea sure,D.E. & Deng,W.Prospects for minocycline neuroprotection.
Arch. Neurol. 67 , 144 2–1 448 (2010).
132. Imbesi,M., Uz,T., M an ev,R., Sharma,R.P. &
Manev,H. Minocycline increase s phosp horylation
a ndmembra ne insertion of neuronal GluR1 receptors.
Neurosci. Let t . 447 , 134 –13 7 (200 8).
13 3. Kobayashi,K. etal. Minocycline selectively inhibits
M1 polarization of microglia. Cell Death Dis. 4, e525
(2013).
134. Wang,X. etal. Rifampin inhibits Toll-like rece pto r 4
signaling by targeting myeloid differentiation pro tein 2
and a ttenuate s neuropat hic pain. FASEB J. 27 ,
2713– 2722 (2013).
13 5. Lewis,S.S. etal. (+ )-naloxone, an opioid-inactive
toll-like rece ptor 4 signaling inhibitor, reverses
multiple models of chronic neuropathic pain in rats.
J.Pain 13 , 498– 506 (2012).
13 6. Hutchinson,M.R. etal. Opioid-induced glial
activation: mechanisms of activation and implications
for opioid analgesia, d ependence, and reward.ScientificWorldJournal.7, 98 –111 (2007 ).
The firs t rep ort de monstra t ing that opioids signal
via TLR4.
13 7. Hutchinson,M.R. etal. Evidence t hat tricyclic sma ll
molecules may possess toll-like receptor and myeloid
differentiation protein 2 activity. Neuroscience 168,
551–563 (2010).
138. Nagata,K. etal. Antidepressant s inhibit P 2X4
recep tor function: a possible involvement in
neuropathic pain relief. Mol. Pain 5, 2 0 (20 09 ).
139. Anand,P. etal. Clinical trial of the p3 8 M AP kinase
inhibitor d ilmap imod in neu ropat hic pain following
nerve injury. Eur. J.Pain 15 , 1040– 1048 (2011).
140. Ji,R.R., Xu,Z.Z., Strichartz,G. & Serhan,C.N.
Emerging roles of resolvins in the resolution
of inflamma tion and pain. Trends Neu rosci. 34 ,
599–609 (2011).
141. Xu,Z.Z. etal. Resolvins RvE1 and RvD1 a ttenuate
inflammatory pain via central and peripheral actions.
Nature Med. 16, 59 2–5 97 (2010).
142. Simonato,M. etal. Progress in gene thera py
forneurological disorders. Nature Rev. Neurol. 9,277–2 91 (2013).
143. Soderquist,R.G. etal. Release of plasmid
DNA-encoding IL-10 from PLGA microparticles
facilitates long-term reversal of neuropathic pain
following a single intratheca l administrat ion.
Pharm. Res. 27, 841– 854 (2010).
144. Shi,Y., Gelma n,B.B., Lisinicchia,J.G. & Tan g,S.J.
Chronic-pain-associated astrocytic reaction in the spinal
cord dorsa l horn of huma n immunode ficiency virus-
infected pa tients. J.Neurosci. 32, 108 33– 10840
(2012).
14 5. De l Valle,L., Schwartzman,R.J. & Alexander,G.
Spinal cord histopathological alterations in a patient
with longstanding complex regional pain syndrome.
Brain Behav. Immun. 23 , 85– 91 (200 9).
146 . Alexander,G.M., van Rijn,M.A., van Hilten,J.J.,
Perreault,M.J. & Schwartzman,R.J. Changes in
cereb rospinal fluid levels of pro-inflam mat ory
cytokines in CRPS. Pain 116 , 213 –21 9 (200 5).
147. Syberg,S. etal. Association between P2X7 receptor
polymorphisms and bone sta tus in mice.
J.Osteoporos 2012 , 63798 6 (2012 ).
148 . Hutchinson,M.R. etal. Low-dose en dotoxin
potentiates capsaicin-induced pain in man: evidence
for a pain neuroimmune connection. Brain Behav.
Immun. 30, 3 –11 (2013).
14 9. Kallioma ki,J. etal. A randomized, double-blind,
placebo-controlled trial of a chemokine receptor 2
(CCR2) antagonist in posttraumatic neuralgia.
Pain 15 4, 761– 767 (2013 ).
150. Banati,R.B. etal. Long-term tra ns-synaptic glial
responses in the human thalamus after peripheral
nerve injury. Neuroreport 12, 3439–3442 (2001).
151 . Trapp ,B.D. & Nave,K.A. Multiple sclerosis: an
immune or neurodegenerat ive disorder? Annu. Rev.
Neurosci. 31, 24 7–2 69 (200 8).
152. Robberecht,W. & Philips,T. The cha nging scene of
amyotrophic lateral sclerosis. Nature Rev. Neurosci.
14 , 248 –264 (2013) .
153 . Grace,P.M., Watkins,L.R. & Hutchinson,M.R. in
Pain Comorbidities: Understa nding and Trea tingthe Complex Patient 1st edn (eds Giamberardino,M.
& Jensen,T.) 137 –1 56 (IASP Press, 20 12 ).
154. Mogil,J.S. Animal mode ls of pain: progress and
challenges. Nature Rev. Neurosci. 10, 2 83 –2 94 (2009 ).
155. Bennett,G.J. & Xie,Y.K. A periphe ral
mononeuropathy in rat tha t produces disorders of
pain sensation like those see n in man. Pain 33 ,
87–107 (1988) .
156 . Seltzer,Z., Dubner,R. & Shir,Y. A novel be ha vioral
model of neuropathic pain disorders produced in rats
by partial sciatic nerve injury. Pain 43 , 20 5– 218
(1990).
157 . Kim,S.H. & Chung,J.M. An experimental model for
peripheral neuropathy produced b y segmental spinal
nerve ligation in the rat. Pain 50, 35 5– 36 3 (199 2).
158 . Grace,P.M., Hutchinson,M.R., Mana vis,J.,
Somogyi,A.A. & Rolan,P.E. A novel animal mo del
of graded neuropathic pain: utility to investigate
mechanisms of population heterogeneity.
J.Neurosci.Methods 19 3, 47–5 3 (2010).159. Polomano,R.C., Mannes,A.J., Clark,U.S. &
Bennett,G.J. A painful peripheral neuropathy in
th erat produced by the chemot herapeutic drug,
pacli taxel. Pain 94, 293 –30 4 (2001 ).
160. Sloane,E. eta l. Anti-inflam ma tory cytokine gene
therap y decreases sens ory and motor dysfunction in
experimental multiple sclerosis: MOG-EAE behavioral
and a natomical symptom t reatm ent with cytokine
gene therapy. Brain Behav. Immun. 23, 92–100
(2009).
161. King,T. eta l. Unma sking the tonic-aversive state in
neuropathic pain. Nature Neurosci. 12 , 13 64– 136 6
(2009).
162 . Langford,D.J. eta l. Coding of facial expressions o f
pain in the laboratory mouse. Nature Me thods 7,
447–4 49 (2010).
163 . Grace,P.M., Strand,K.A., Maier,S.F. &
Watkins,L.R. Suppres sion of voluntary wheel running
in rats is dependent on the site of inflammation:
evidence for voluntary running as a measure of
hindpaw-evoked pain. J. Pain. 15 , 121– 12 8 (2014 ).
164. Monassi,C.R., Bandler,R. & Keay,K.A. Asubpopulation of rats show social and sleep-waking
changes typical of chronic neuropathic pain
followingper ipheral ne rve injury. Eur. J.Neurosci. 17,
1907–19 20 (2003).
165 . Mogil,J.S., Davis,K.D. & Derbyshire,S.W.
Thenecessity of animal models in pain research.
Pain151 , 1 2–17 (2010).
166. Scott,F.T. etal. A study of shingles and the
development of postherpetic neuralgia in East
London. J.Med. Virol. 70, S24 –S3 0 (200 3).
16 7. Kleibeuker,W. e ta l. IL-1β signaling is required for
mecha nical allodynia induced by nerve injury and
for the ensuing reduction in spinal cord neurona l
GRK2. Brain Behav. Immun. 22 , 20 0–2 08 (20 08 ).
168. Kleibeuker,W. e tal. A role for G protein-coupled
receptor kinase 2 in mechanical allodynia.
Eur. J.Neurosci. 25, 16 96– 1704 (2007).
169. Willemen,H.L. etal. Microglial/macrop hage GRK2
determines duration of peripheral IL-1 β-induced
hyperalgesia: contr ibution of spinal cord CX3CR1, 3 8
and IL-1 signaling. Pain 150 , 550 –5 60 (2010).
170. Loram,L.C. etal. Prior exposure to glucocorticoids
potentiates lipopolysaccharide induced mechanical
allodynia and spinal neuroinflammation. Brain Behav.
Immun. 25 , 1408 –141 5 (2011).
171. Hains,L.E. etal. Prior laparotomy or corticosterone
potentiates lipopolysaccharide-induced fever and
sickness behaviors. J.Neuroimmunol. 23 9, 5 3–6 0
(2011).
172 . Hains,L.E. etal. Pain intensity and d uration can
be enha nced b y prior challenge: initial evidence
suggest ive of a role of microglial priming. J.Pain 11,
1004–1014 (2010).
173. Loram,L.C. etal. Prior exposure to repea ted
morphine pot entiates mechanical allodynia induced
by peripheral inflammation and neuropathy.
BrainBehav. Immun. 26, 125 6–1 264 (2012 ).
174. Hutchinson,M.R. etal. Exploring the
neuroimmunopha rmacology of opioids: an
integrative re view of mecha nisms of central immune
signaling and their implications for o pioid a nalgesia.Pharmacol . Rev. 63 , 77 2– 810 (2011).
A comprehensive review of opioid-induced central
immune signalling.
175. Wang,X. etal. Morphine activates neuroinflammation
in a ma nner pa rallel to endotoxin. Proc. Natl Acad.
Sci. USA 109 , 632 5–6 330 (2012 ).
176 . Hutchinson,M.R. & Watkins,L.R. Why is
neuroimmunopharmacology crucial for the future of
addiction research? Neuropha rmacology 76 Pt B,
218–227 (2013) .
17 7. Ferrini,F. etal. Morphine hyperalgesia gated
through m icroglia-mediated disruption of neurona l
Cl– homeostasis . Nature Neurosci. 16 , 183 –1 92
(2013).
AcknowledgementsFunding source s: P.M.G. is a CJ Mart in Fellow of the Austra lian
Government National Health and Medical Research Council
and an American Australian Association Sir Keith Murdoch
Fellow. M.R.H. is an Australian Resea rch Council Fellow.
Compet ing interests s ta tementThe authors declare no competing interests.
DATABASESClinicalTrials.gov: http://clinicaltrials.gov/
NCT01317992 |NCT01982942
ALL LINKS ARE ACTIVE IN THE ONLINE PDF
REVIEWS
NATURE REVIEWS | IMMUNOLOGY VOLUME 14 | APRIL 2014 | 231
Recommended